<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="nl">
	<id>https://zibs.test-nictiz.nl/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Ali+Zada</id>
	<title>Zorginformatiebouwstenen - Gebruikersbijdragen [nl]</title>
	<link rel="self" type="application/atom+xml" href="https://zibs.test-nictiz.nl/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Ali+Zada"/>
	<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/wiki/Speciaal:Bijdragen/Ali_Zada"/>
	<updated>2026-04-29T22:50:37Z</updated>
	<subtitle>Gebruikersbijdragen</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=23526</id>
		<title>HCIM Release 2021(EN)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=23526"/>
		<updated>2021-12-14T14:29:47Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Prerelease 2021-2 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:HCIM Prerelease 2021-2(EN)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(EN)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Prerelease 2021-2 ==&lt;br /&gt;
This is a prerelease. More information about prereleases and releases you can find [[HCIM_Mainpage#Release and maintenance process | here]].&amp;lt;br&amp;gt;&lt;br /&gt;
The following summary shows which hcim&#039;s are part of this release, including the version numbers.&amp;lt;BR&amp;gt;&lt;br /&gt;
More information on Prerelease 2021-2 you can find in the [[Media:Prepublicatieversie_2021-2_-_Zorginformatiebouwstenen.pdf|ReleaseNotes 2021]] [[File:PDF.png|link=]] (in Dutch) and in the [[#New information models and deprecated information models in release 2020 | sections below]].&lt;br /&gt;
&lt;br /&gt;
== Health and care information models prerelease&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Administrative, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareTeam-v1.0.1(2021EN)|CareTeam-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Encounter-v4.0.2(2021EN)|Encounter-v4.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[HealthProfessional-v3.5.1(2021EN)|HealthProfessional-v3.5.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Payer-v3.2(2021EN)|Payer-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ContactPerson-v3.5(2021EN)|ContactPerson-v3.5]]&lt;br /&gt;
|[[HealthcareProvider-v3.4(2021EN)|HealthcareProvider-v3.4]]&lt;br /&gt;
|[[Patient-v4.0(2021EN)|Patient-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Clinical context, count&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021EN)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FeedingPatternInfant-v1.1.1(2021EN)|FeedingPatternInfant-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MultidisciplinaryTeamMeeting-v1.1(2021EN)|MultidisciplinaryTeamMeeting-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[SkinDisorder-v3.4(2021EN)|SkinDisorder-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergyIntolerance-v4.0(2021EN)|AllergyIntolerance-v4.0]]&lt;br /&gt;
|[[FeedingTubeSystem-v3.3.1(2021EN)|FeedingTubeSystem-v3.3.1]]&lt;br /&gt;
|[[NutritionAdvice-v3.2(2021EN)|NutritionAdvice-v3.2]]&lt;br /&gt;
|[[SOAPReport-v1.1(2021EN)|SOAPReport-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BladderFunction-v3.2(2021EN)|BladderFunction-v3.2]]&lt;br /&gt;
|[[FunctionalOrMentalStatus-v3.2.1(2021EN)|FunctionalOrMentalStatus-v3.2.1]]&lt;br /&gt;
|[[PainCharacteristics-v1.0(2021EN)|PainCharacteristics-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021EN)|Stoma-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BowelFunction-v3.1.2(2021EN)|BowelFunction-v3.1.2]]&lt;br /&gt;
|[[HearingFunction-v3.2.1(2021EN)|HearingFunction-v3.2.1]]&lt;br /&gt;
|[[Pregnancy-v4.1(2021EN)|Pregnancy-v4.1]]&lt;br /&gt;
|[[Vaccination-v4.1(2021EN)|Vaccination-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Burnwound-v3.5(2021EN)|Burnwound-v3.5]]&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|[[PressureUlcer-v3.4(2021EN)|PressureUlcer-v3.4]]&lt;br /&gt;
|[[VisualFunction-v3.3(2021EN)|VisualFunction-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DevelopmentChild-v1.2(2021EN)|DevelopmentChild-v1.2]]&lt;br /&gt;
|[[Infusion-v3.4(2021EN)|Infusion-v3.4]]&lt;br /&gt;
|[[Problem-v4.5(2021EN)|Problem-v4.5]]&lt;br /&gt;
|[[Wound-v3.4(2021EN)|Wound-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[EpisodeOfCare-v1.0(2021EN)|EpisodeOfCare-v1.0]]&lt;br /&gt;
|[[MedicalDevice-v3.4(2021EN)|MedicalDevice-v3.4]]&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Measurements, count&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BloodPressure-v3.2.1(2021EN)|BloodPressure-v3.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DAS-v1.1(2021EN)|DAS-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoryTestResult-v5.0(2021EN)|LaboratoryTestResult-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Respiration-v3.2(2021EN)|Respiration-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyHeight-v3.1.1(2021EN)|BodyHeight-v3.1.1]]&lt;br /&gt;
|[[FluidBalance-v1.0.1(2021EN)|FluidBalance-v1.0.1]]&lt;br /&gt;
|[[O2Saturation-v4.0(2021EN)|O2Saturation-v4.0]]&lt;br /&gt;
|[[TextResult-v4.4(2021EN)|TextResult-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyTemperature-v3.1.2(2021EN)|BodyTemperature-v3.1.2]]&lt;br /&gt;
|[[HeadCircumference-v1.3(2021EN)|HeadCircumference-v1.3]]&lt;br /&gt;
|[[PulseRate-v3.3(2021EN)|PulseRate-v3.3]]&lt;br /&gt;
|[[VisualAcuity-v2.0(2021EN)|VisualAcuity-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyWeight-v3.2(2021EN)|BodyWeight-v3.2]]&lt;br /&gt;
|[[HeartRate-v3.4.1(2021EN)|HeartRate-v3.4.1]]&lt;br /&gt;
|[[Refraction-v1.1(2021EN)|Refraction-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Medication, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdministrationAgreement-v1.1(2021EN)|AdministrationAgreement-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationAdministration2-v1.1.1(2021EN)|MedicationAdministration2-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationContraIndication-v1.1(2021EN)|MedicationContraIndication-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationUse2-v1.2(2021EN)|MedicationUse2-v1.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DispenseRequest-v1.1(2021EN)|DispenseRequest-v1.1]]&lt;br /&gt;
|[[MedicationAgreement-v1.3(2021EN)|MedicationAgreement-v1.3]]&lt;br /&gt;
|[[MedicationDispense-v2.1(2021EN)|MedicationDispense-v2.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Partial information models, count&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AddressInformation-v1.1(2021EN)|AddressInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ContactInformation-v1.2.1(2021EN)|ContactInformation-v1.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NameInformation-v1.1(2021EN)|NameInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Range-v1.0.1(2021EN)|Range-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomicalLocation-v1.0.1(2021EN)|AnatomicalLocation-v1.0.1]]&lt;br /&gt;
|[[InstructionsForUse-v1.3(2021EN)|InstructionsForUse-v1.3]]&lt;br /&gt;
|[[PharmaceuticalProduct-v2.1.3(2021EN)|PharmaceuticalProduct-v2.1.3]]&lt;br /&gt;
|[[TimeInterval-v1.1(2021EN)|TimeInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Patient context, count&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdvanceDirective-v4.0(2021EN)|AdvanceDirective-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FamilySituation-v3.3(2021EN)|FamilySituation-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LegalSituation-v3.0(2021EN)|LegalSituation-v3.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ParticipationInSociety-v3.1(2021EN)|ParticipationInSociety-v3.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AlcoholUse-v3.3(2021EN)|AlcoholUse-v3.3]]&lt;br /&gt;
|[[FamilySituationChild-v1.3(2021EN)|FamilySituationChild-v1.3]]&lt;br /&gt;
|[[LifeStance-v3.2.1(2021EN)|LifeStance-v3.2.1]]&lt;br /&gt;
|[[TobaccoUse-v3.3(2021EN)|TobaccoUse-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugUse-v3.4(2021EN)|DrugUse-v3.4]]&lt;br /&gt;
|[[HelpFromOthers-v3.01(2021EN)|HelpFromOthers-v3.01]]&lt;br /&gt;
|[[LivingSituation-v3.4(2021EN)|LivingSituation-v3.4]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Education-v3.2(2021EN)|Education-v3.2]]&lt;br /&gt;
|[[IllnessPerception-v3.1.1(2021EN)|IllnessPerception-v3.1.1]]&lt;br /&gt;
|[[MaritalStatus-v3.1(2021EN)|MaritalStatus-v3.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[FamilyHistory-v3.2(2021EN)|FamilyHistory-v3.2]]&lt;br /&gt;
|[[LanguageProficiency-v3.2(2021EN)|LanguageProficiency-v3.2]]&lt;br /&gt;
|[[Nationality-v3.0(2021EN)|Nationality-v3.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Scales en screening tools, count&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021EN)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021EN)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[PainScore-v4.0(2021EN)|PainScore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021EN)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelADLIndex-v3.1(2021EN)|BarthelADLIndex-v3.1]]&lt;br /&gt;
|[[FLACCpainScale-v1.1(2021EN)|FLACCpainScale-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021EN)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassification-v2.0(2021EN)|TNMTumorClassification-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPainBehavior-v1.1(2021EN)|ChecklistPainBehavior-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021EN)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021EN)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScale-v1.1(2021EN)|ComfortScale-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021EN)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021EN)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Selfcare, count&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToDressOneself-v3.1.1(2021EN)|AbilityToDressOneself-v3.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToGroom-v1.0.2(2021EN)|AbilityToGroom-v1.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToPerformNursingActivities-v1.0.1(2021EN)|AbilityToPerformNursingActivities-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ToiletUseAbility-v3.1.1(2021EN)|ToiletUseAbility-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToDrink-v3.1.2(2021EN)|AbilityToDrink-v3.1.2]]&lt;br /&gt;
|[[AbilityToManageMedication-v1.0.1(2021EN)|AbilityToManageMedication-v1.0.1]]&lt;br /&gt;
|[[AbilityToWashOneself-v3.1.1(2021EN)|AbilityToWashOneself-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToEat-v3.1.1(2021EN)|AbilityToEat-v3.1.1]]&lt;br /&gt;
|[[AbilityToPerformMouthcareActivities-v3.1(2021EN)|AbilityToPerformMouthcareActivities-v3.1]]&lt;br /&gt;
|[[Mobility-v3.3.1(2021EN)|Mobility-v3.3.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Treatment, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareAgreement-v1.0(2021EN)|CareAgreement-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NursingIntervention-v4.0(2021EN)|NursingIntervention-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Procedure-v5.3(2021EN)|Procedure-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TreatmentObjective-v3.2(2021EN)|TreatmentObjective-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FreedomRestrictingIntervention-v1.1(2021EN)|FreedomRestrictingIntervention-v1.1]]&lt;br /&gt;
|[[OutcomeOfCare-v3.3(2021EN)|OutcomeOfCare-v3.3]]&lt;br /&gt;
|[[TreatmentDirective2-v1.0(2021EN)|TreatmentDirective2-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== New information models in prerelease 2021-2 ==&lt;br /&gt;
In prerelease 2021-2 a number of new information models are added to the national set of HCIM&#039;s.&amp;lt;br&amp;gt;&lt;br /&gt;
===New HCIM&#039;s===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Pre-release 2021-2 was published by adhering to a novel improved pre-publication procedure of the HCIM. For more information, click [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ here]. One of the features of this improved procedure method is that important changes to existing HCIMs and new HCIMs are first published in a pre-release and will no longer automatically end up in the next release. The new Hypersensitivity and Reaction HCIMs are examples of new HCIMs that are now being published in pre-release so that they can be used in a limited number of use cases. For that limited number of use cases, the new Hypersensitivity and Reaction HCIMs replace the existing Allergy Intolerance HCIM. In accordance with the improved procedure or pre-release, the decision whether these 2 new HCIMs will replace the existing Allergy Intolerance HCIM will be taken later in the preparations for a new release. As a consequence, the existing Allergy Intolerance HCIM is also still included in this pre-release, in addition to the 2 new HCIMs mentioned. Allergy Intolerance will remain valid for use cases for which the new Hypersensitivity and Reaction HCIMs will not be used.&lt;br /&gt;
&lt;br /&gt;
== Special information models ==&lt;br /&gt;
{{HCIM_PartialInformationModels_Include}}&lt;br /&gt;
{{HCIM_Templates_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
At the bottom of each HCIM wikipage you can find links to download the HCIM information in PDF of XLSX format.&amp;lt;BR&amp;gt;&lt;br /&gt;
It is also possible to download the whole set of HCIM&#039;s of this release in one file as [[Media:HCIM2020(PDF).zip |PDF]][[File:ZIP.png|link=]](80 MB), [[Media:HCIM2020(XLSX).zip|XLSX]][[File:ZIP.png|link=]] or [[Media:ZIBS2020(XMI).zip |XMI]][[File:ZIP.png|link=]]. The last file also contains valuelist in XML format.&lt;br /&gt;
&lt;br /&gt;
== Additional information ==&lt;br /&gt;
NEW!&lt;br /&gt;
* Starting from prepublication 2018-1, LOINC and SNOMED CT terms are displayed in Dutch wikipages in Dutch and in English wikipages in English, if an official translation is available.&lt;br /&gt;
:Attention! Publication 2020 contains many newly created SNOMED CT codes. These codes are not yet included in the current SNOMED CT release at the time of publication. As a result, these codes are incorrectly referred to as &#039;unknown code&#039;.&lt;br /&gt;
: This will be resolved after the new SNOMED CT release.&lt;br /&gt;
* A section has been added to each HCIM wikipage indicating which other HCIM&#039;s the building block refers to and in which other HCIM&#039;s the HCIM is used.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23525</id>
		<title>ZIB Publicatie 2021(NL)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23525"/>
		<updated>2021-12-14T14:29:21Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Pre-publicatie 2021-2 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:Zib Pre-publicatie 2021-2(NL)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(NL)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Pre-publicatie 2021-2 ==&lt;br /&gt;
Dit is een pre-publicatie. Meer informatie over pre-publicaties en publicaties is [[ZIB_Hoofdpagina#Publicatie en beheersproces | hier]] te vinden.&amp;lt;br&amp;gt;&lt;br /&gt;
In onderstaand overzicht staat aangegeven welke zibs deel uitmaken van deze publicatie inclusief de versienummers.&amp;lt;BR&amp;gt;&lt;br /&gt;
Meer informatie over de pre-publicatie 2021-2 kunt u vinden in de [[Media:Prepublicatieversie_2021-2_-_Zorginformatiebouwstenen.pdf |ReleaseNotes 2021-2]] [[File:PDF.png|link=]] en de [[#Nieuwe bouwstenen in pre-publicatie 2021-2 | secties hieronder]].&lt;br /&gt;
&lt;br /&gt;
== Zorginformatiebouwstenen pre-publicatie&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Administratief, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Betaler-v3.2(2021NL)|Betaler-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Contactpersoon-v3.5(2021NL)|Contactpersoon-v3.5]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgaanbieder-v3.4(2021NL)|Zorgaanbieder-v3.4]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgverlener-v3.5.1(2021NL)|Zorgverlener-v3.5.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Contact-v4.0.2(2021NL)|Contact-v4.0.2]]&lt;br /&gt;
|[[Patient-v4.0(2021NL)|Patient-v4.0]]&lt;br /&gt;
|[[ZorgTeam-v1.0.1(2021NL)|ZorgTeam-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Behandeling, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BehandelAanwijzing2-v1.0(2021NL)|BehandelAanwijzing2-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[UitkomstVanZorg-v3.3(2021NL)|UitkomstVanZorg-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verrichting-v5.3(2021NL)|Verrichting-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ZorgAfspraak-v1.0(2021NL)|ZorgAfspraak-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Behandeldoel-v3.2(2021NL)|Behandeldoel-v3.2]]&lt;br /&gt;
|[[VerpleegkundigeInterventie-v4.0(2021NL)|VerpleegkundigeInterventie-v4.0]]&lt;br /&gt;
|[[VrijheidsbeperkendeInterventie-v1.1(2021NL)|VrijheidsbeperkendeInterventie-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Klinische context, aantal&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021NL)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FunctieZien-v3.3(2021NL)|FunctieZien-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Patientbespreking-v1.1(2021NL)|Patientbespreking-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Vaccinatie-v4.1(2021NL)|Vaccinatie-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergieIntolerantie-v4.0(2021NL)|AllergieIntolerantie-v4.0]]&lt;br /&gt;
|[[FunctioneleOfMentaleStatus-v3.2.1(2021NL)|FunctioneleOfMentaleStatus-v3.2.1]]&lt;br /&gt;
|[[Pijnkenmerken-v1.0(2021NL)|Pijnkenmerken-v1.0]]&lt;br /&gt;
|[[Voedingsadvies-v3.2(2021NL)|Voedingsadvies-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Blaasfunctie-v3.2(2021NL)|Blaasfunctie-v3.2]]&lt;br /&gt;
|[[Huidaandoening-v3.4(2021NL)|Huidaandoening-v3.4]]&lt;br /&gt;
|[[Probleem-v4.5(2021NL)|Probleem-v4.5]]&lt;br /&gt;
|[[VoedingspatroonZuigeling-v1.1.1(2021NL)|VoedingspatroonZuigeling-v1.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Brandwond-v3.5(2021NL)|Brandwond-v3.5]]&lt;br /&gt;
|[[Infuus-v3.4(2021NL)|Infuus-v3.4]]&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|[[Wond-v3.4(2021NL)|Wond-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Darmfunctie-v3.1.2(2021NL)|Darmfunctie-v3.1.2]]&lt;br /&gt;
|[[MedischHulpmiddel-v3.4(2021NL)|MedischHulpmiddel-v3.4]]&lt;br /&gt;
|[[SOEPVerslag-v1.1(2021NL)|SOEPVerslag-v1.1]]&lt;br /&gt;
|[[ZorgEpisode-v1.0(2021NL)|ZorgEpisode-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DecubitusWond-v3.4(2021NL)|DecubitusWond-v3.4]]&lt;br /&gt;
|[[OntwikkelingKind-v1.2(2021NL)|OntwikkelingKind-v1.2]]&lt;br /&gt;
|[[SondeSysteem-v3.3.1(2021NL)|SondeSysteem-v3.3.1]]&lt;br /&gt;
|[[Zwangerschap-v4.1(2021NL)|Zwangerschap-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FunctieHoren-v3.2.1(2021NL)|FunctieHoren-v3.2.1]]&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021NL)|Stoma-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Medicatie, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieafspraak-v1.3(2021NL)|Medicatieafspraak-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicatieGebruik2-v1.2(2021NL)|MedicatieGebruik2-v1.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieverstrekking-v2.1(2021NL)|Medicatieverstrekking-v2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verstrekkingsverzoek-v1.1(2021NL)|Verstrekkingsverzoek-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[MedicatieContraIndicatie-v1.1(2021NL)|MedicatieContraIndicatie-v1.1]]&lt;br /&gt;
|[[MedicatieToediening2-v1.1.1(2021NL)|MedicatieToediening2-v1.1.1]]&lt;br /&gt;
|[[Toedieningsafspraak-v1.1(2021NL)|Toedieningsafspraak-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Metingen, aantal&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Ademhaling-v3.2(2021NL)|Ademhaling-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoriumUitslag-v5.0(2021NL)|LaboratoriumUitslag-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[O2Saturatie-v4.0(2021NL)|O2Saturatie-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TekstUitslag-v4.4(2021NL)|TekstUitslag-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Bloeddruk-v3.2.1(2021NL)|Bloeddruk-v3.2.1]]&lt;br /&gt;
|[[Lichaamsgewicht-v3.2(2021NL)|Lichaamsgewicht-v3.2]]&lt;br /&gt;
|[[Polsfrequentie-v3.3(2021NL)|Polsfrequentie-v3.3]]&lt;br /&gt;
|[[Visus-v2.0(2021NL)|Visus-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DAS-v1.1(2021NL)|DAS-v1.1]]&lt;br /&gt;
|[[Lichaamslengte-v3.1.1(2021NL)|Lichaamslengte-v3.1.1]]&lt;br /&gt;
|[[Refractie-v1.1(2021NL)|Refractie-v1.1]]&lt;br /&gt;
|[[Vochtbalans-v1.0.1(2021NL)|Vochtbalans-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hartfrequentie-v3.4.1(2021NL)|Hartfrequentie-v3.4.1]]&lt;br /&gt;
|[[Lichaamstemperatuur-v3.1.2(2021NL)|Lichaamstemperatuur-v3.1.2]]&lt;br /&gt;
|[[Schedelomvang-v1.3(2021NL)|Schedelomvang-v1.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Patiënten context, aantal&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AlcoholGebruik-v3.3(2021NL)|AlcoholGebruik-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[GezinssituatieKind-v1.3(2021NL)|GezinssituatieKind-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Opleiding-v3.2(2021NL)|Opleiding-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Woonsituatie-v3.4(2021NL)|Woonsituatie-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BurgerlijkeStaat-v3.1(2021NL)|BurgerlijkeStaat-v3.1]]&lt;br /&gt;
|[[HulpVanAnderen-v3.01(2021NL)|HulpVanAnderen-v3.01]]&lt;br /&gt;
|[[ParticipatieInMaatschappij-v3.1(2021NL)|ParticipatieInMaatschappij-v3.1]]&lt;br /&gt;
|[[Ziektebeleving-v3.1.1(2021NL)|Ziektebeleving-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugsGebruik-v3.4(2021NL)|DrugsGebruik-v3.4]]&lt;br /&gt;
|[[JuridischeSituatie-v3.0(2021NL)|JuridischeSituatie-v3.0]]&lt;br /&gt;
|[[Taalvaardigheid-v3.2(2021NL)|Taalvaardigheid-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Familieanamnese-v3.2(2021NL)|Familieanamnese-v3.2]]&lt;br /&gt;
|[[Levensovertuiging-v3.2.1(2021NL)|Levensovertuiging-v3.2.1]]&lt;br /&gt;
|[[TabakGebruik-v3.3(2021NL)|TabakGebruik-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Gezinssituatie-v3.3(2021NL)|Gezinssituatie-v3.3]]&lt;br /&gt;
|[[Nationaliteit-v3.0(2021NL)|Nationaliteit-v3.0]]&lt;br /&gt;
|[[Wilsverklaring-v4.0(2021NL)|Wilsverklaring-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Scorelijsten, aantal&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021NL)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021NL)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Pijnscore-v4.0(2021NL)|Pijnscore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021NL)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelIndex-v3.1(2021NL)|BarthelIndex-v3.1]]&lt;br /&gt;
|[[FLACCpijnScore-v1.1(2021NL)|FLACCpijnScore-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021NL)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassificatie-v2.0(2021NL)|TNMTumorClassificatie-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPijngedrag-v1.1(2021NL)|ChecklistPijngedrag-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021NL)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021NL)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScore-v1.1(2021NL)|ComfortScore-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021NL)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021NL)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Subbouwstenen, aantal&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Adresgegevens-v1.1(2021NL)|Adresgegevens-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Bereik-v1.0.1(2021NL)|Bereik-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FarmaceutischProduct-v2.1.3(2021NL)|FarmaceutischProduct-v2.1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Naamgegevens-v1.1(2021NL)|Naamgegevens-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomischeLocatie-v1.0.1(2021NL)|AnatomischeLocatie-v1.0.1]]&lt;br /&gt;
|[[Contactgegevens-v1.2.1(2021NL)|Contactgegevens-v1.2.1]]&lt;br /&gt;
|[[GebruiksInstructie-v1.3(2021NL)|GebruiksInstructie-v1.3]]&lt;br /&gt;
|[[TijdsInterval-v1.1(2021NL)|TijdsInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Zelfzorg, aantal&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Mobiliteit-v3.3.1(2021NL)|Mobiliteit-v3.3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotMondverzorging-v3.1(2021NL)|VermogenTotMondverzorging-v3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotVerpleegtechnischeHandelingen-v1.0.1(2021NL)|VermogenTotVerpleegtechnischeHandelingen-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotZichWassen-v3.1.1(2021NL)|VermogenTotZichWassen-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotDrinken-v3.1.2(2021NL)|VermogenTotDrinken-v3.1.2]]&lt;br /&gt;
|[[VermogenTotToiletgang-v3.1.1(2021NL)|VermogenTotToiletgang-v3.1.1]]&lt;br /&gt;
|[[VermogenTotZelfstandigMedicatiegebruik-v1.0.1(2021NL)|VermogenTotZelfstandigMedicatiegebruik-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotEten-v3.1.1(2021NL)|VermogenTotEten-v3.1.1]]&lt;br /&gt;
|[[VermogenTotUiterlijkeVerzorging-v1.0.2(2021NL)|VermogenTotUiterlijkeVerzorging-v1.0.2]]&lt;br /&gt;
|[[VermogenTotZichKleden-v3.1.1(2021NL)|VermogenTotZichKleden-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== Nieuwe bouwstenen in pre-publicatie 2021-2==&lt;br /&gt;
In pre-publicatie 2021-2 zijn een aantal nieuwe bouwstenen toegevoegd aan de landelijke set van zibs.&lt;br /&gt;
===Nieuwe zibs===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Pre-publicatie  2021-2 is tot stand gekomen door de verbeterde opzet voor pre-publicatie van de zibs toe te passen. Zie voor meer informatie [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ hier]. Een van de kenmerken van deze verbeterde opzet is dat belangrijke wijzigingen op bestaande zibs en nieuwe zibs eerst in een pre-publicatie gepubliceerd worden en niet meer automatisch in de eerst volgende publicatie terecht komen. De nieuwe zibs Overgevoeligheid en Reactie zijn voorbeelden van nieuwe zibs die nu in pre-Publicatie worden gepubliceerd, zodat ze voor een beperkt aantal use cases kunnen worden toegepast. Voor die beperkt aantal use cases vervangen de nieuwe zibs Overgevoeligheid en Reactie de bestaande zib AllergieIntollerantie. Conform de verbeterde opzet van pre-Publicaties wordt het besluit of deze 2 nieuwe zibs de bestaande zib AllergieIntollerantie vervangen, later, in de voorbereidingen voor een nieuwe Publicatie genomen. Het gevolg hiervan is dat, naast de genoemde 2 nieuwe zibs, ook de bestaande zib AllergieIntollerantie nog in deze pre-Publicatie staat opgenomen: deze blijft immers geldig voor de use cases, die de nieuwe zibs Overgevoeligheid en Reactie (nog) niet toepassen.&lt;br /&gt;
&lt;br /&gt;
== Speciale bouwstenen ==&lt;br /&gt;
{{ZIB_Subbouwstenen_Include}}&lt;br /&gt;
{{ZIB_Blauwdrukken_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
Onderaan de iedere ZIB wikipagina staan links om de betreffende ZIB in PDF of XLSX formaat te downlowden.&amp;lt;BR&amp;gt;&lt;br /&gt;
Ook is het mogelijk de hele set ZIB&#039;s van deze publicatie in één keer te downloaden als [[Media:ZIBS2021-2(PDF).zip |PDF]][[File:ZIP.png|link=]](74 MB), [[Media:ZIBS2021-2(XLSX).zip|XLSX]][[File:ZIP.png|link=]] of [[Media:ZIBS2021-2(XMI).zip |XMI]][[File:ZIP.png|link=]] bestanden. De laatste bevat tevens de waardenlijsten in XML formaat.&lt;br /&gt;
&lt;br /&gt;
== Overige punten ==&lt;br /&gt;
NIEUW!&lt;br /&gt;
*Vanaf prepublicatie 2018#1 worden LOINC en SNOMED CT termen, indien een officiële vertaling beschikbaar is, in de Nedelandse pagina&#039;s in het Nederlands weergegeven en in de Engelse in het Engels.&lt;br /&gt;
:Let op! Publicatie 2020 bevat veel nieuw aangemaakte SNOMED CT codes. Deze codes zitten op moment van publicatie nog niet in de huidige SNOMED CT release. Daardoor worden deze codes foutief aangeduid als &#039;onbekende code&#039;.&lt;br /&gt;
:Na het verschijnen van de nieuwe SNOMED CT release wordt dit opgelost.&lt;br /&gt;
*Aan iedere zib wiki pagina is een sectie toegevoegd die aangeeft naar welke andere zibs de bouwsteen verwijst en in welke andere zibs de zib wordt gebruikt.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23524</id>
		<title>ZIB Publicatie 2021(NL)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23524"/>
		<updated>2021-12-14T14:28:24Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Pre-publicatie 2021-2 */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:Zib Pre-publicatie 2021-2(NL)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(NL)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Pre-publicatie 2021-2 ==&lt;br /&gt;
Dit is een pre-publicatie. Meer informatie over pre-publicaties en publicaties is [[ZIB_Hoofdpagina#Publicatie en beheersproces | hier]] te vinden.&amp;lt;br&amp;gt;&lt;br /&gt;
In onderstaand overzicht staat aangegeven welke zibs deel uitmaken van deze publicatie inclusief de versienummers.&amp;lt;BR&amp;gt;&lt;br /&gt;
Meer informatie over de pre-publicatie 2021-2 kunt u vinden in de [[Media:Prepublicatieversie 2021-2 Zorginformatiebouwstenen.pdf |ReleaseNotes 2021-2]] [[File:PDF.png|link=]] en de [[#Nieuwe bouwstenen in pre-publicatie 2021-2 | secties hieronder]].&lt;br /&gt;
&lt;br /&gt;
== Zorginformatiebouwstenen pre-publicatie&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Administratief, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Betaler-v3.2(2021NL)|Betaler-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Contactpersoon-v3.5(2021NL)|Contactpersoon-v3.5]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgaanbieder-v3.4(2021NL)|Zorgaanbieder-v3.4]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgverlener-v3.5.1(2021NL)|Zorgverlener-v3.5.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Contact-v4.0.2(2021NL)|Contact-v4.0.2]]&lt;br /&gt;
|[[Patient-v4.0(2021NL)|Patient-v4.0]]&lt;br /&gt;
|[[ZorgTeam-v1.0.1(2021NL)|ZorgTeam-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Behandeling, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BehandelAanwijzing2-v1.0(2021NL)|BehandelAanwijzing2-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[UitkomstVanZorg-v3.3(2021NL)|UitkomstVanZorg-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verrichting-v5.3(2021NL)|Verrichting-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ZorgAfspraak-v1.0(2021NL)|ZorgAfspraak-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Behandeldoel-v3.2(2021NL)|Behandeldoel-v3.2]]&lt;br /&gt;
|[[VerpleegkundigeInterventie-v4.0(2021NL)|VerpleegkundigeInterventie-v4.0]]&lt;br /&gt;
|[[VrijheidsbeperkendeInterventie-v1.1(2021NL)|VrijheidsbeperkendeInterventie-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Klinische context, aantal&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021NL)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FunctieZien-v3.3(2021NL)|FunctieZien-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Patientbespreking-v1.1(2021NL)|Patientbespreking-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Vaccinatie-v4.1(2021NL)|Vaccinatie-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergieIntolerantie-v4.0(2021NL)|AllergieIntolerantie-v4.0]]&lt;br /&gt;
|[[FunctioneleOfMentaleStatus-v3.2.1(2021NL)|FunctioneleOfMentaleStatus-v3.2.1]]&lt;br /&gt;
|[[Pijnkenmerken-v1.0(2021NL)|Pijnkenmerken-v1.0]]&lt;br /&gt;
|[[Voedingsadvies-v3.2(2021NL)|Voedingsadvies-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Blaasfunctie-v3.2(2021NL)|Blaasfunctie-v3.2]]&lt;br /&gt;
|[[Huidaandoening-v3.4(2021NL)|Huidaandoening-v3.4]]&lt;br /&gt;
|[[Probleem-v4.5(2021NL)|Probleem-v4.5]]&lt;br /&gt;
|[[VoedingspatroonZuigeling-v1.1.1(2021NL)|VoedingspatroonZuigeling-v1.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Brandwond-v3.5(2021NL)|Brandwond-v3.5]]&lt;br /&gt;
|[[Infuus-v3.4(2021NL)|Infuus-v3.4]]&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|[[Wond-v3.4(2021NL)|Wond-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Darmfunctie-v3.1.2(2021NL)|Darmfunctie-v3.1.2]]&lt;br /&gt;
|[[MedischHulpmiddel-v3.4(2021NL)|MedischHulpmiddel-v3.4]]&lt;br /&gt;
|[[SOEPVerslag-v1.1(2021NL)|SOEPVerslag-v1.1]]&lt;br /&gt;
|[[ZorgEpisode-v1.0(2021NL)|ZorgEpisode-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DecubitusWond-v3.4(2021NL)|DecubitusWond-v3.4]]&lt;br /&gt;
|[[OntwikkelingKind-v1.2(2021NL)|OntwikkelingKind-v1.2]]&lt;br /&gt;
|[[SondeSysteem-v3.3.1(2021NL)|SondeSysteem-v3.3.1]]&lt;br /&gt;
|[[Zwangerschap-v4.1(2021NL)|Zwangerschap-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FunctieHoren-v3.2.1(2021NL)|FunctieHoren-v3.2.1]]&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021NL)|Stoma-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Medicatie, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieafspraak-v1.3(2021NL)|Medicatieafspraak-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicatieGebruik2-v1.2(2021NL)|MedicatieGebruik2-v1.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieverstrekking-v2.1(2021NL)|Medicatieverstrekking-v2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verstrekkingsverzoek-v1.1(2021NL)|Verstrekkingsverzoek-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[MedicatieContraIndicatie-v1.1(2021NL)|MedicatieContraIndicatie-v1.1]]&lt;br /&gt;
|[[MedicatieToediening2-v1.1.1(2021NL)|MedicatieToediening2-v1.1.1]]&lt;br /&gt;
|[[Toedieningsafspraak-v1.1(2021NL)|Toedieningsafspraak-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Metingen, aantal&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Ademhaling-v3.2(2021NL)|Ademhaling-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoriumUitslag-v5.0(2021NL)|LaboratoriumUitslag-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[O2Saturatie-v4.0(2021NL)|O2Saturatie-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TekstUitslag-v4.4(2021NL)|TekstUitslag-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Bloeddruk-v3.2.1(2021NL)|Bloeddruk-v3.2.1]]&lt;br /&gt;
|[[Lichaamsgewicht-v3.2(2021NL)|Lichaamsgewicht-v3.2]]&lt;br /&gt;
|[[Polsfrequentie-v3.3(2021NL)|Polsfrequentie-v3.3]]&lt;br /&gt;
|[[Visus-v2.0(2021NL)|Visus-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DAS-v1.1(2021NL)|DAS-v1.1]]&lt;br /&gt;
|[[Lichaamslengte-v3.1.1(2021NL)|Lichaamslengte-v3.1.1]]&lt;br /&gt;
|[[Refractie-v1.1(2021NL)|Refractie-v1.1]]&lt;br /&gt;
|[[Vochtbalans-v1.0.1(2021NL)|Vochtbalans-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hartfrequentie-v3.4.1(2021NL)|Hartfrequentie-v3.4.1]]&lt;br /&gt;
|[[Lichaamstemperatuur-v3.1.2(2021NL)|Lichaamstemperatuur-v3.1.2]]&lt;br /&gt;
|[[Schedelomvang-v1.3(2021NL)|Schedelomvang-v1.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Patiënten context, aantal&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AlcoholGebruik-v3.3(2021NL)|AlcoholGebruik-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[GezinssituatieKind-v1.3(2021NL)|GezinssituatieKind-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Opleiding-v3.2(2021NL)|Opleiding-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Woonsituatie-v3.4(2021NL)|Woonsituatie-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BurgerlijkeStaat-v3.1(2021NL)|BurgerlijkeStaat-v3.1]]&lt;br /&gt;
|[[HulpVanAnderen-v3.01(2021NL)|HulpVanAnderen-v3.01]]&lt;br /&gt;
|[[ParticipatieInMaatschappij-v3.1(2021NL)|ParticipatieInMaatschappij-v3.1]]&lt;br /&gt;
|[[Ziektebeleving-v3.1.1(2021NL)|Ziektebeleving-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugsGebruik-v3.4(2021NL)|DrugsGebruik-v3.4]]&lt;br /&gt;
|[[JuridischeSituatie-v3.0(2021NL)|JuridischeSituatie-v3.0]]&lt;br /&gt;
|[[Taalvaardigheid-v3.2(2021NL)|Taalvaardigheid-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Familieanamnese-v3.2(2021NL)|Familieanamnese-v3.2]]&lt;br /&gt;
|[[Levensovertuiging-v3.2.1(2021NL)|Levensovertuiging-v3.2.1]]&lt;br /&gt;
|[[TabakGebruik-v3.3(2021NL)|TabakGebruik-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Gezinssituatie-v3.3(2021NL)|Gezinssituatie-v3.3]]&lt;br /&gt;
|[[Nationaliteit-v3.0(2021NL)|Nationaliteit-v3.0]]&lt;br /&gt;
|[[Wilsverklaring-v4.0(2021NL)|Wilsverklaring-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Scorelijsten, aantal&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021NL)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021NL)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Pijnscore-v4.0(2021NL)|Pijnscore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021NL)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelIndex-v3.1(2021NL)|BarthelIndex-v3.1]]&lt;br /&gt;
|[[FLACCpijnScore-v1.1(2021NL)|FLACCpijnScore-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021NL)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassificatie-v2.0(2021NL)|TNMTumorClassificatie-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPijngedrag-v1.1(2021NL)|ChecklistPijngedrag-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021NL)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021NL)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScore-v1.1(2021NL)|ComfortScore-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021NL)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021NL)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Subbouwstenen, aantal&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Adresgegevens-v1.1(2021NL)|Adresgegevens-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Bereik-v1.0.1(2021NL)|Bereik-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FarmaceutischProduct-v2.1.3(2021NL)|FarmaceutischProduct-v2.1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Naamgegevens-v1.1(2021NL)|Naamgegevens-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomischeLocatie-v1.0.1(2021NL)|AnatomischeLocatie-v1.0.1]]&lt;br /&gt;
|[[Contactgegevens-v1.2.1(2021NL)|Contactgegevens-v1.2.1]]&lt;br /&gt;
|[[GebruiksInstructie-v1.3(2021NL)|GebruiksInstructie-v1.3]]&lt;br /&gt;
|[[TijdsInterval-v1.1(2021NL)|TijdsInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Zelfzorg, aantal&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Mobiliteit-v3.3.1(2021NL)|Mobiliteit-v3.3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotMondverzorging-v3.1(2021NL)|VermogenTotMondverzorging-v3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotVerpleegtechnischeHandelingen-v1.0.1(2021NL)|VermogenTotVerpleegtechnischeHandelingen-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotZichWassen-v3.1.1(2021NL)|VermogenTotZichWassen-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotDrinken-v3.1.2(2021NL)|VermogenTotDrinken-v3.1.2]]&lt;br /&gt;
|[[VermogenTotToiletgang-v3.1.1(2021NL)|VermogenTotToiletgang-v3.1.1]]&lt;br /&gt;
|[[VermogenTotZelfstandigMedicatiegebruik-v1.0.1(2021NL)|VermogenTotZelfstandigMedicatiegebruik-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotEten-v3.1.1(2021NL)|VermogenTotEten-v3.1.1]]&lt;br /&gt;
|[[VermogenTotUiterlijkeVerzorging-v1.0.2(2021NL)|VermogenTotUiterlijkeVerzorging-v1.0.2]]&lt;br /&gt;
|[[VermogenTotZichKleden-v3.1.1(2021NL)|VermogenTotZichKleden-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== Nieuwe bouwstenen in pre-publicatie 2021-2==&lt;br /&gt;
In pre-publicatie 2021-2 zijn een aantal nieuwe bouwstenen toegevoegd aan de landelijke set van zibs.&lt;br /&gt;
===Nieuwe zibs===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Pre-publicatie  2021-2 is tot stand gekomen door de verbeterde opzet voor pre-publicatie van de zibs toe te passen. Zie voor meer informatie [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ hier]. Een van de kenmerken van deze verbeterde opzet is dat belangrijke wijzigingen op bestaande zibs en nieuwe zibs eerst in een pre-publicatie gepubliceerd worden en niet meer automatisch in de eerst volgende publicatie terecht komen. De nieuwe zibs Overgevoeligheid en Reactie zijn voorbeelden van nieuwe zibs die nu in pre-Publicatie worden gepubliceerd, zodat ze voor een beperkt aantal use cases kunnen worden toegepast. Voor die beperkt aantal use cases vervangen de nieuwe zibs Overgevoeligheid en Reactie de bestaande zib AllergieIntollerantie. Conform de verbeterde opzet van pre-Publicaties wordt het besluit of deze 2 nieuwe zibs de bestaande zib AllergieIntollerantie vervangen, later, in de voorbereidingen voor een nieuwe Publicatie genomen. Het gevolg hiervan is dat, naast de genoemde 2 nieuwe zibs, ook de bestaande zib AllergieIntollerantie nog in deze pre-Publicatie staat opgenomen: deze blijft immers geldig voor de use cases, die de nieuwe zibs Overgevoeligheid en Reactie (nog) niet toepassen.&lt;br /&gt;
&lt;br /&gt;
== Speciale bouwstenen ==&lt;br /&gt;
{{ZIB_Subbouwstenen_Include}}&lt;br /&gt;
{{ZIB_Blauwdrukken_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
Onderaan de iedere ZIB wikipagina staan links om de betreffende ZIB in PDF of XLSX formaat te downlowden.&amp;lt;BR&amp;gt;&lt;br /&gt;
Ook is het mogelijk de hele set ZIB&#039;s van deze publicatie in één keer te downloaden als [[Media:ZIBS2021-2(PDF).zip |PDF]][[File:ZIP.png|link=]](74 MB), [[Media:ZIBS2021-2(XLSX).zip|XLSX]][[File:ZIP.png|link=]] of [[Media:ZIBS2021-2(XMI).zip |XMI]][[File:ZIP.png|link=]] bestanden. De laatste bevat tevens de waardenlijsten in XML formaat.&lt;br /&gt;
&lt;br /&gt;
== Overige punten ==&lt;br /&gt;
NIEUW!&lt;br /&gt;
*Vanaf prepublicatie 2018#1 worden LOINC en SNOMED CT termen, indien een officiële vertaling beschikbaar is, in de Nedelandse pagina&#039;s in het Nederlands weergegeven en in de Engelse in het Engels.&lt;br /&gt;
:Let op! Publicatie 2020 bevat veel nieuw aangemaakte SNOMED CT codes. Deze codes zitten op moment van publicatie nog niet in de huidige SNOMED CT release. Daardoor worden deze codes foutief aangeduid als &#039;onbekende code&#039;.&lt;br /&gt;
:Na het verschijnen van de nieuwe SNOMED CT release wordt dit opgelost.&lt;br /&gt;
*Aan iedere zib wiki pagina is een sectie toegevoegd die aangeeft naar welke andere zibs de bouwsteen verwijst en in welke andere zibs de zib wordt gebruikt.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=Bestand:Prepublicatieversie_2021-2_-_Zorginformatiebouwstenen.pdf&amp;diff=23523</id>
		<title>Bestand:Prepublicatieversie 2021-2 - Zorginformatiebouwstenen.pdf</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=Bestand:Prepublicatieversie_2021-2_-_Zorginformatiebouwstenen.pdf&amp;diff=23523"/>
		<updated>2021-12-14T14:27:26Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=23522</id>
		<title>HCIM Release 2021(EN)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=23522"/>
		<updated>2021-12-14T14:25:56Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Downloads */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:HCIM Prerelease 2021-2(EN)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(EN)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Prerelease 2021-2 ==&lt;br /&gt;
This is a prerelease. More information about prereleases and releases you can find [[HCIM_Mainpage#Release and maintenance process | here]].&amp;lt;br&amp;gt;&lt;br /&gt;
The following summary shows which hcim&#039;s are part of this release, including the version numbers.&amp;lt;BR&amp;gt;&lt;br /&gt;
More information on Prerelease 2021-2 you can find in the [[Media:Prepublicatieversie 2021-2- Zorginformatiebouwstenen.pdf|ReleaseNotes 2021]] [[File:PDF.png|link=]] (in Dutch) and in the [[#New information models and deprecated information models in release 2020 | sections below]].&lt;br /&gt;
&lt;br /&gt;
== Health and care information models prerelease&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Administrative, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareTeam-v1.0.1(2021EN)|CareTeam-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Encounter-v4.0.2(2021EN)|Encounter-v4.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[HealthProfessional-v3.5.1(2021EN)|HealthProfessional-v3.5.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Payer-v3.2(2021EN)|Payer-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ContactPerson-v3.5(2021EN)|ContactPerson-v3.5]]&lt;br /&gt;
|[[HealthcareProvider-v3.4(2021EN)|HealthcareProvider-v3.4]]&lt;br /&gt;
|[[Patient-v4.0(2021EN)|Patient-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Clinical context, count&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021EN)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FeedingPatternInfant-v1.1.1(2021EN)|FeedingPatternInfant-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MultidisciplinaryTeamMeeting-v1.1(2021EN)|MultidisciplinaryTeamMeeting-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[SkinDisorder-v3.4(2021EN)|SkinDisorder-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergyIntolerance-v4.0(2021EN)|AllergyIntolerance-v4.0]]&lt;br /&gt;
|[[FeedingTubeSystem-v3.3.1(2021EN)|FeedingTubeSystem-v3.3.1]]&lt;br /&gt;
|[[NutritionAdvice-v3.2(2021EN)|NutritionAdvice-v3.2]]&lt;br /&gt;
|[[SOAPReport-v1.1(2021EN)|SOAPReport-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BladderFunction-v3.2(2021EN)|BladderFunction-v3.2]]&lt;br /&gt;
|[[FunctionalOrMentalStatus-v3.2.1(2021EN)|FunctionalOrMentalStatus-v3.2.1]]&lt;br /&gt;
|[[PainCharacteristics-v1.0(2021EN)|PainCharacteristics-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021EN)|Stoma-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BowelFunction-v3.1.2(2021EN)|BowelFunction-v3.1.2]]&lt;br /&gt;
|[[HearingFunction-v3.2.1(2021EN)|HearingFunction-v3.2.1]]&lt;br /&gt;
|[[Pregnancy-v4.1(2021EN)|Pregnancy-v4.1]]&lt;br /&gt;
|[[Vaccination-v4.1(2021EN)|Vaccination-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Burnwound-v3.5(2021EN)|Burnwound-v3.5]]&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|[[PressureUlcer-v3.4(2021EN)|PressureUlcer-v3.4]]&lt;br /&gt;
|[[VisualFunction-v3.3(2021EN)|VisualFunction-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DevelopmentChild-v1.2(2021EN)|DevelopmentChild-v1.2]]&lt;br /&gt;
|[[Infusion-v3.4(2021EN)|Infusion-v3.4]]&lt;br /&gt;
|[[Problem-v4.5(2021EN)|Problem-v4.5]]&lt;br /&gt;
|[[Wound-v3.4(2021EN)|Wound-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[EpisodeOfCare-v1.0(2021EN)|EpisodeOfCare-v1.0]]&lt;br /&gt;
|[[MedicalDevice-v3.4(2021EN)|MedicalDevice-v3.4]]&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Measurements, count&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BloodPressure-v3.2.1(2021EN)|BloodPressure-v3.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DAS-v1.1(2021EN)|DAS-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoryTestResult-v5.0(2021EN)|LaboratoryTestResult-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Respiration-v3.2(2021EN)|Respiration-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyHeight-v3.1.1(2021EN)|BodyHeight-v3.1.1]]&lt;br /&gt;
|[[FluidBalance-v1.0.1(2021EN)|FluidBalance-v1.0.1]]&lt;br /&gt;
|[[O2Saturation-v4.0(2021EN)|O2Saturation-v4.0]]&lt;br /&gt;
|[[TextResult-v4.4(2021EN)|TextResult-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyTemperature-v3.1.2(2021EN)|BodyTemperature-v3.1.2]]&lt;br /&gt;
|[[HeadCircumference-v1.3(2021EN)|HeadCircumference-v1.3]]&lt;br /&gt;
|[[PulseRate-v3.3(2021EN)|PulseRate-v3.3]]&lt;br /&gt;
|[[VisualAcuity-v2.0(2021EN)|VisualAcuity-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyWeight-v3.2(2021EN)|BodyWeight-v3.2]]&lt;br /&gt;
|[[HeartRate-v3.4.1(2021EN)|HeartRate-v3.4.1]]&lt;br /&gt;
|[[Refraction-v1.1(2021EN)|Refraction-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Medication, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdministrationAgreement-v1.1(2021EN)|AdministrationAgreement-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationAdministration2-v1.1.1(2021EN)|MedicationAdministration2-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationContraIndication-v1.1(2021EN)|MedicationContraIndication-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationUse2-v1.2(2021EN)|MedicationUse2-v1.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DispenseRequest-v1.1(2021EN)|DispenseRequest-v1.1]]&lt;br /&gt;
|[[MedicationAgreement-v1.3(2021EN)|MedicationAgreement-v1.3]]&lt;br /&gt;
|[[MedicationDispense-v2.1(2021EN)|MedicationDispense-v2.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Partial information models, count&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AddressInformation-v1.1(2021EN)|AddressInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ContactInformation-v1.2.1(2021EN)|ContactInformation-v1.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NameInformation-v1.1(2021EN)|NameInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Range-v1.0.1(2021EN)|Range-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomicalLocation-v1.0.1(2021EN)|AnatomicalLocation-v1.0.1]]&lt;br /&gt;
|[[InstructionsForUse-v1.3(2021EN)|InstructionsForUse-v1.3]]&lt;br /&gt;
|[[PharmaceuticalProduct-v2.1.3(2021EN)|PharmaceuticalProduct-v2.1.3]]&lt;br /&gt;
|[[TimeInterval-v1.1(2021EN)|TimeInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Patient context, count&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdvanceDirective-v4.0(2021EN)|AdvanceDirective-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FamilySituation-v3.3(2021EN)|FamilySituation-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LegalSituation-v3.0(2021EN)|LegalSituation-v3.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ParticipationInSociety-v3.1(2021EN)|ParticipationInSociety-v3.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AlcoholUse-v3.3(2021EN)|AlcoholUse-v3.3]]&lt;br /&gt;
|[[FamilySituationChild-v1.3(2021EN)|FamilySituationChild-v1.3]]&lt;br /&gt;
|[[LifeStance-v3.2.1(2021EN)|LifeStance-v3.2.1]]&lt;br /&gt;
|[[TobaccoUse-v3.3(2021EN)|TobaccoUse-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugUse-v3.4(2021EN)|DrugUse-v3.4]]&lt;br /&gt;
|[[HelpFromOthers-v3.01(2021EN)|HelpFromOthers-v3.01]]&lt;br /&gt;
|[[LivingSituation-v3.4(2021EN)|LivingSituation-v3.4]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Education-v3.2(2021EN)|Education-v3.2]]&lt;br /&gt;
|[[IllnessPerception-v3.1.1(2021EN)|IllnessPerception-v3.1.1]]&lt;br /&gt;
|[[MaritalStatus-v3.1(2021EN)|MaritalStatus-v3.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[FamilyHistory-v3.2(2021EN)|FamilyHistory-v3.2]]&lt;br /&gt;
|[[LanguageProficiency-v3.2(2021EN)|LanguageProficiency-v3.2]]&lt;br /&gt;
|[[Nationality-v3.0(2021EN)|Nationality-v3.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Scales en screening tools, count&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021EN)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021EN)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[PainScore-v4.0(2021EN)|PainScore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021EN)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelADLIndex-v3.1(2021EN)|BarthelADLIndex-v3.1]]&lt;br /&gt;
|[[FLACCpainScale-v1.1(2021EN)|FLACCpainScale-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021EN)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassification-v2.0(2021EN)|TNMTumorClassification-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPainBehavior-v1.1(2021EN)|ChecklistPainBehavior-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021EN)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021EN)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScale-v1.1(2021EN)|ComfortScale-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021EN)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021EN)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Selfcare, count&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToDressOneself-v3.1.1(2021EN)|AbilityToDressOneself-v3.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToGroom-v1.0.2(2021EN)|AbilityToGroom-v1.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToPerformNursingActivities-v1.0.1(2021EN)|AbilityToPerformNursingActivities-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ToiletUseAbility-v3.1.1(2021EN)|ToiletUseAbility-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToDrink-v3.1.2(2021EN)|AbilityToDrink-v3.1.2]]&lt;br /&gt;
|[[AbilityToManageMedication-v1.0.1(2021EN)|AbilityToManageMedication-v1.0.1]]&lt;br /&gt;
|[[AbilityToWashOneself-v3.1.1(2021EN)|AbilityToWashOneself-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToEat-v3.1.1(2021EN)|AbilityToEat-v3.1.1]]&lt;br /&gt;
|[[AbilityToPerformMouthcareActivities-v3.1(2021EN)|AbilityToPerformMouthcareActivities-v3.1]]&lt;br /&gt;
|[[Mobility-v3.3.1(2021EN)|Mobility-v3.3.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Treatment, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareAgreement-v1.0(2021EN)|CareAgreement-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NursingIntervention-v4.0(2021EN)|NursingIntervention-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Procedure-v5.3(2021EN)|Procedure-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TreatmentObjective-v3.2(2021EN)|TreatmentObjective-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FreedomRestrictingIntervention-v1.1(2021EN)|FreedomRestrictingIntervention-v1.1]]&lt;br /&gt;
|[[OutcomeOfCare-v3.3(2021EN)|OutcomeOfCare-v3.3]]&lt;br /&gt;
|[[TreatmentDirective2-v1.0(2021EN)|TreatmentDirective2-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== New information models in prerelease 2021-2 ==&lt;br /&gt;
In prerelease 2021-2 a number of new information models are added to the national set of HCIM&#039;s.&amp;lt;br&amp;gt;&lt;br /&gt;
===New HCIM&#039;s===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Pre-release 2021-2 was published by adhering to a novel improved pre-publication procedure of the HCIM. For more information, click [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ here]. One of the features of this improved procedure method is that important changes to existing HCIMs and new HCIMs are first published in a pre-release and will no longer automatically end up in the next release. The new Hypersensitivity and Reaction HCIMs are examples of new HCIMs that are now being published in pre-release so that they can be used in a limited number of use cases. For that limited number of use cases, the new Hypersensitivity and Reaction HCIMs replace the existing Allergy Intolerance HCIM. In accordance with the improved procedure or pre-release, the decision whether these 2 new HCIMs will replace the existing Allergy Intolerance HCIM will be taken later in the preparations for a new release. As a consequence, the existing Allergy Intolerance HCIM is also still included in this pre-release, in addition to the 2 new HCIMs mentioned. Allergy Intolerance will remain valid for use cases for which the new Hypersensitivity and Reaction HCIMs will not be used.&lt;br /&gt;
&lt;br /&gt;
== Special information models ==&lt;br /&gt;
{{HCIM_PartialInformationModels_Include}}&lt;br /&gt;
{{HCIM_Templates_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
At the bottom of each HCIM wikipage you can find links to download the HCIM information in PDF of XLSX format.&amp;lt;BR&amp;gt;&lt;br /&gt;
It is also possible to download the whole set of HCIM&#039;s of this release in one file as [[Media:HCIM2020(PDF).zip |PDF]][[File:ZIP.png|link=]](80 MB), [[Media:HCIM2020(XLSX).zip|XLSX]][[File:ZIP.png|link=]] or [[Media:ZIBS2020(XMI).zip |XMI]][[File:ZIP.png|link=]]. The last file also contains valuelist in XML format.&lt;br /&gt;
&lt;br /&gt;
== Additional information ==&lt;br /&gt;
NEW!&lt;br /&gt;
* Starting from prepublication 2018-1, LOINC and SNOMED CT terms are displayed in Dutch wikipages in Dutch and in English wikipages in English, if an official translation is available.&lt;br /&gt;
:Attention! Publication 2020 contains many newly created SNOMED CT codes. These codes are not yet included in the current SNOMED CT release at the time of publication. As a result, these codes are incorrectly referred to as &#039;unknown code&#039;.&lt;br /&gt;
: This will be resolved after the new SNOMED CT release.&lt;br /&gt;
* A section has been added to each HCIM wikipage indicating which other HCIM&#039;s the building block refers to and in which other HCIM&#039;s the HCIM is used.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23521</id>
		<title>ZIB Publicatie 2021(NL)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=23521"/>
		<updated>2021-12-14T14:25:26Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Downloads */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:Zib Pre-publicatie 2021-2(NL)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(NL)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Pre-publicatie 2021-2 ==&lt;br /&gt;
Dit is een pre-publicatie. Meer informatie over pre-publicaties en publicaties is [[ZIB_Hoofdpagina#Publicatie en beheersproces | hier]] te vinden.&amp;lt;br&amp;gt;&lt;br /&gt;
In onderstaand overzicht staat aangegeven welke zibs deel uitmaken van deze publicatie inclusief de versienummers.&amp;lt;BR&amp;gt;&lt;br /&gt;
Meer informatie over de pre-publicatie 2021-2 kunt u vinden in de [[Media:Prepublicatieversie 2021-2- Zorginformatiebouwstenen.pdf |ReleaseNotes 2021-2]] [[File:PDF.png|link=]] en de [[#Nieuwe bouwstenen in pre-publicatie 2021-2 | secties hieronder]].&lt;br /&gt;
&lt;br /&gt;
== Zorginformatiebouwstenen pre-publicatie&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Administratief, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Betaler-v3.2(2021NL)|Betaler-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Contactpersoon-v3.5(2021NL)|Contactpersoon-v3.5]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgaanbieder-v3.4(2021NL)|Zorgaanbieder-v3.4]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgverlener-v3.5.1(2021NL)|Zorgverlener-v3.5.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Contact-v4.0.2(2021NL)|Contact-v4.0.2]]&lt;br /&gt;
|[[Patient-v4.0(2021NL)|Patient-v4.0]]&lt;br /&gt;
|[[ZorgTeam-v1.0.1(2021NL)|ZorgTeam-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Behandeling, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BehandelAanwijzing2-v1.0(2021NL)|BehandelAanwijzing2-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[UitkomstVanZorg-v3.3(2021NL)|UitkomstVanZorg-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verrichting-v5.3(2021NL)|Verrichting-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ZorgAfspraak-v1.0(2021NL)|ZorgAfspraak-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Behandeldoel-v3.2(2021NL)|Behandeldoel-v3.2]]&lt;br /&gt;
|[[VerpleegkundigeInterventie-v4.0(2021NL)|VerpleegkundigeInterventie-v4.0]]&lt;br /&gt;
|[[VrijheidsbeperkendeInterventie-v1.1(2021NL)|VrijheidsbeperkendeInterventie-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Klinische context, aantal&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021NL)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FunctieZien-v3.3(2021NL)|FunctieZien-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Patientbespreking-v1.1(2021NL)|Patientbespreking-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Vaccinatie-v4.1(2021NL)|Vaccinatie-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergieIntolerantie-v4.0(2021NL)|AllergieIntolerantie-v4.0]]&lt;br /&gt;
|[[FunctioneleOfMentaleStatus-v3.2.1(2021NL)|FunctioneleOfMentaleStatus-v3.2.1]]&lt;br /&gt;
|[[Pijnkenmerken-v1.0(2021NL)|Pijnkenmerken-v1.0]]&lt;br /&gt;
|[[Voedingsadvies-v3.2(2021NL)|Voedingsadvies-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Blaasfunctie-v3.2(2021NL)|Blaasfunctie-v3.2]]&lt;br /&gt;
|[[Huidaandoening-v3.4(2021NL)|Huidaandoening-v3.4]]&lt;br /&gt;
|[[Probleem-v4.5(2021NL)|Probleem-v4.5]]&lt;br /&gt;
|[[VoedingspatroonZuigeling-v1.1.1(2021NL)|VoedingspatroonZuigeling-v1.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Brandwond-v3.5(2021NL)|Brandwond-v3.5]]&lt;br /&gt;
|[[Infuus-v3.4(2021NL)|Infuus-v3.4]]&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|[[Wond-v3.4(2021NL)|Wond-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Darmfunctie-v3.1.2(2021NL)|Darmfunctie-v3.1.2]]&lt;br /&gt;
|[[MedischHulpmiddel-v3.4(2021NL)|MedischHulpmiddel-v3.4]]&lt;br /&gt;
|[[SOEPVerslag-v1.1(2021NL)|SOEPVerslag-v1.1]]&lt;br /&gt;
|[[ZorgEpisode-v1.0(2021NL)|ZorgEpisode-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DecubitusWond-v3.4(2021NL)|DecubitusWond-v3.4]]&lt;br /&gt;
|[[OntwikkelingKind-v1.2(2021NL)|OntwikkelingKind-v1.2]]&lt;br /&gt;
|[[SondeSysteem-v3.3.1(2021NL)|SondeSysteem-v3.3.1]]&lt;br /&gt;
|[[Zwangerschap-v4.1(2021NL)|Zwangerschap-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FunctieHoren-v3.2.1(2021NL)|FunctieHoren-v3.2.1]]&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021NL)|Stoma-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Medicatie, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieafspraak-v1.3(2021NL)|Medicatieafspraak-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicatieGebruik2-v1.2(2021NL)|MedicatieGebruik2-v1.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieverstrekking-v2.1(2021NL)|Medicatieverstrekking-v2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verstrekkingsverzoek-v1.1(2021NL)|Verstrekkingsverzoek-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[MedicatieContraIndicatie-v1.1(2021NL)|MedicatieContraIndicatie-v1.1]]&lt;br /&gt;
|[[MedicatieToediening2-v1.1.1(2021NL)|MedicatieToediening2-v1.1.1]]&lt;br /&gt;
|[[Toedieningsafspraak-v1.1(2021NL)|Toedieningsafspraak-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Metingen, aantal&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Ademhaling-v3.2(2021NL)|Ademhaling-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoriumUitslag-v5.0(2021NL)|LaboratoriumUitslag-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[O2Saturatie-v4.0(2021NL)|O2Saturatie-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TekstUitslag-v4.4(2021NL)|TekstUitslag-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Bloeddruk-v3.2.1(2021NL)|Bloeddruk-v3.2.1]]&lt;br /&gt;
|[[Lichaamsgewicht-v3.2(2021NL)|Lichaamsgewicht-v3.2]]&lt;br /&gt;
|[[Polsfrequentie-v3.3(2021NL)|Polsfrequentie-v3.3]]&lt;br /&gt;
|[[Visus-v2.0(2021NL)|Visus-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DAS-v1.1(2021NL)|DAS-v1.1]]&lt;br /&gt;
|[[Lichaamslengte-v3.1.1(2021NL)|Lichaamslengte-v3.1.1]]&lt;br /&gt;
|[[Refractie-v1.1(2021NL)|Refractie-v1.1]]&lt;br /&gt;
|[[Vochtbalans-v1.0.1(2021NL)|Vochtbalans-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hartfrequentie-v3.4.1(2021NL)|Hartfrequentie-v3.4.1]]&lt;br /&gt;
|[[Lichaamstemperatuur-v3.1.2(2021NL)|Lichaamstemperatuur-v3.1.2]]&lt;br /&gt;
|[[Schedelomvang-v1.3(2021NL)|Schedelomvang-v1.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Patiënten context, aantal&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AlcoholGebruik-v3.3(2021NL)|AlcoholGebruik-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[GezinssituatieKind-v1.3(2021NL)|GezinssituatieKind-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Opleiding-v3.2(2021NL)|Opleiding-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Woonsituatie-v3.4(2021NL)|Woonsituatie-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BurgerlijkeStaat-v3.1(2021NL)|BurgerlijkeStaat-v3.1]]&lt;br /&gt;
|[[HulpVanAnderen-v3.01(2021NL)|HulpVanAnderen-v3.01]]&lt;br /&gt;
|[[ParticipatieInMaatschappij-v3.1(2021NL)|ParticipatieInMaatschappij-v3.1]]&lt;br /&gt;
|[[Ziektebeleving-v3.1.1(2021NL)|Ziektebeleving-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugsGebruik-v3.4(2021NL)|DrugsGebruik-v3.4]]&lt;br /&gt;
|[[JuridischeSituatie-v3.0(2021NL)|JuridischeSituatie-v3.0]]&lt;br /&gt;
|[[Taalvaardigheid-v3.2(2021NL)|Taalvaardigheid-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Familieanamnese-v3.2(2021NL)|Familieanamnese-v3.2]]&lt;br /&gt;
|[[Levensovertuiging-v3.2.1(2021NL)|Levensovertuiging-v3.2.1]]&lt;br /&gt;
|[[TabakGebruik-v3.3(2021NL)|TabakGebruik-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Gezinssituatie-v3.3(2021NL)|Gezinssituatie-v3.3]]&lt;br /&gt;
|[[Nationaliteit-v3.0(2021NL)|Nationaliteit-v3.0]]&lt;br /&gt;
|[[Wilsverklaring-v4.0(2021NL)|Wilsverklaring-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Scorelijsten, aantal&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021NL)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021NL)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Pijnscore-v4.0(2021NL)|Pijnscore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021NL)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelIndex-v3.1(2021NL)|BarthelIndex-v3.1]]&lt;br /&gt;
|[[FLACCpijnScore-v1.1(2021NL)|FLACCpijnScore-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021NL)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassificatie-v2.0(2021NL)|TNMTumorClassificatie-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPijngedrag-v1.1(2021NL)|ChecklistPijngedrag-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021NL)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021NL)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScore-v1.1(2021NL)|ComfortScore-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021NL)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021NL)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Subbouwstenen, aantal&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Adresgegevens-v1.1(2021NL)|Adresgegevens-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Bereik-v1.0.1(2021NL)|Bereik-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FarmaceutischProduct-v2.1.3(2021NL)|FarmaceutischProduct-v2.1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Naamgegevens-v1.1(2021NL)|Naamgegevens-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomischeLocatie-v1.0.1(2021NL)|AnatomischeLocatie-v1.0.1]]&lt;br /&gt;
|[[Contactgegevens-v1.2.1(2021NL)|Contactgegevens-v1.2.1]]&lt;br /&gt;
|[[GebruiksInstructie-v1.3(2021NL)|GebruiksInstructie-v1.3]]&lt;br /&gt;
|[[TijdsInterval-v1.1(2021NL)|TijdsInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Zelfzorg, aantal&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Mobiliteit-v3.3.1(2021NL)|Mobiliteit-v3.3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotMondverzorging-v3.1(2021NL)|VermogenTotMondverzorging-v3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotVerpleegtechnischeHandelingen-v1.0.1(2021NL)|VermogenTotVerpleegtechnischeHandelingen-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotZichWassen-v3.1.1(2021NL)|VermogenTotZichWassen-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotDrinken-v3.1.2(2021NL)|VermogenTotDrinken-v3.1.2]]&lt;br /&gt;
|[[VermogenTotToiletgang-v3.1.1(2021NL)|VermogenTotToiletgang-v3.1.1]]&lt;br /&gt;
|[[VermogenTotZelfstandigMedicatiegebruik-v1.0.1(2021NL)|VermogenTotZelfstandigMedicatiegebruik-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotEten-v3.1.1(2021NL)|VermogenTotEten-v3.1.1]]&lt;br /&gt;
|[[VermogenTotUiterlijkeVerzorging-v1.0.2(2021NL)|VermogenTotUiterlijkeVerzorging-v1.0.2]]&lt;br /&gt;
|[[VermogenTotZichKleden-v3.1.1(2021NL)|VermogenTotZichKleden-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== Nieuwe bouwstenen in pre-publicatie 2021-2==&lt;br /&gt;
In pre-publicatie 2021-2 zijn een aantal nieuwe bouwstenen toegevoegd aan de landelijke set van zibs.&lt;br /&gt;
===Nieuwe zibs===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Pre-publicatie  2021-2 is tot stand gekomen door de verbeterde opzet voor pre-publicatie van de zibs toe te passen. Zie voor meer informatie [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ hier]. Een van de kenmerken van deze verbeterde opzet is dat belangrijke wijzigingen op bestaande zibs en nieuwe zibs eerst in een pre-publicatie gepubliceerd worden en niet meer automatisch in de eerst volgende publicatie terecht komen. De nieuwe zibs Overgevoeligheid en Reactie zijn voorbeelden van nieuwe zibs die nu in pre-Publicatie worden gepubliceerd, zodat ze voor een beperkt aantal use cases kunnen worden toegepast. Voor die beperkt aantal use cases vervangen de nieuwe zibs Overgevoeligheid en Reactie de bestaande zib AllergieIntollerantie. Conform de verbeterde opzet van pre-Publicaties wordt het besluit of deze 2 nieuwe zibs de bestaande zib AllergieIntollerantie vervangen, later, in de voorbereidingen voor een nieuwe Publicatie genomen. Het gevolg hiervan is dat, naast de genoemde 2 nieuwe zibs, ook de bestaande zib AllergieIntollerantie nog in deze pre-Publicatie staat opgenomen: deze blijft immers geldig voor de use cases, die de nieuwe zibs Overgevoeligheid en Reactie (nog) niet toepassen.&lt;br /&gt;
&lt;br /&gt;
== Speciale bouwstenen ==&lt;br /&gt;
{{ZIB_Subbouwstenen_Include}}&lt;br /&gt;
{{ZIB_Blauwdrukken_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
Onderaan de iedere ZIB wikipagina staan links om de betreffende ZIB in PDF of XLSX formaat te downlowden.&amp;lt;BR&amp;gt;&lt;br /&gt;
Ook is het mogelijk de hele set ZIB&#039;s van deze publicatie in één keer te downloaden als [[Media:ZIBS2021-2(PDF).zip |PDF]][[File:ZIP.png|link=]](74 MB), [[Media:ZIBS2021-2(XLSX).zip|XLSX]][[File:ZIP.png|link=]] of [[Media:ZIBS2021-2(XMI).zip |XMI]][[File:ZIP.png|link=]] bestanden. De laatste bevat tevens de waardenlijsten in XML formaat.&lt;br /&gt;
&lt;br /&gt;
== Overige punten ==&lt;br /&gt;
NIEUW!&lt;br /&gt;
*Vanaf prepublicatie 2018#1 worden LOINC en SNOMED CT termen, indien een officiële vertaling beschikbaar is, in de Nedelandse pagina&#039;s in het Nederlands weergegeven en in de Engelse in het Engels.&lt;br /&gt;
:Let op! Publicatie 2020 bevat veel nieuw aangemaakte SNOMED CT codes. Deze codes zitten op moment van publicatie nog niet in de huidige SNOMED CT release. Daardoor worden deze codes foutief aangeduid als &#039;onbekende code&#039;.&lt;br /&gt;
:Na het verschijnen van de nieuwe SNOMED CT release wordt dit opgelost.&lt;br /&gt;
*Aan iedere zib wiki pagina is een sectie toegevoegd die aangeeft naar welke andere zibs de bouwsteen verwijst en in welke andere zibs de zib wordt gebruikt.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=Hoofdpagina&amp;diff=23515</id>
		<title>Hoofdpagina</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=Hoofdpagina&amp;diff=23515"/>
		<updated>2021-12-14T14:10:51Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Zorginformatiebouwstenen */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Zorginformatiebouwstenen==&lt;br /&gt;
Dit is de landingspagina van de wiki die gewijd is aan de zorginformatie bouwstenen (zibs).&amp;lt;BR&amp;gt;&lt;br /&gt;
Deze pagina geeft toegang tot de [[ZIB_Hoofdpagina|Nederlandstalige hoofdpagina]] [[Bestand:NL.png]] en de [[HCIM_Mainpage|Engelstalige hoofdpagina]] [[Bestand:EN.png]].&amp;lt;BR&amp;gt; &lt;br /&gt;
De hoofdpagina geeft een overzicht van zib publicaties en de daarbij behorende zibs&amp;lt;BR&amp;gt;&lt;br /&gt;
Ook kan meteen voor de [[ZIB_Publicatie_2021(NL)|huidige pre-publicatie]] gekozen worden.&amp;lt;BR&amp;gt;&lt;br /&gt;
&lt;br /&gt;
De factsheets behandelen specifiek onderwerpen rond en over zorginformatiebouwstenen.&amp;lt;BR&amp;gt;&lt;br /&gt;
Het documentatie deel is uitsluitend voor bouwsteenontwerpers, aan verandering onderhevig en niet geversioneerd.&lt;br /&gt;
&lt;br /&gt;
==Health and Care Information models==&lt;br /&gt;
This is the landing page of the wiki dedicated to the health and care information models (HCIM&#039;s). &amp;lt;BR&amp;gt;&lt;br /&gt;
This page gives access to the [[ZIB_Hoofdpagina | Dutch mainpage]] [[File: NL.png]] and the [[HCIM_Mainpage | English mainpage]] [[File: EN.png]]. &amp;lt;BR&amp;gt;&lt;br /&gt;
The main page gives an overview of HCIM publications and the associated HCIM&#039;s &amp;lt;BR&amp;gt;&lt;br /&gt;
&lt;br /&gt;
The factsheets cover specific topics on the use of the healthcare information building blocks (only available in Dutch).&amp;lt;BR&amp;gt;&lt;br /&gt;
The documentation part is for HCIM designers only, subject to change and not versioned (only available in Dutch).&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=HCIM_Mainpage&amp;diff=23514</id>
		<title>HCIM Mainpage</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=HCIM_Mainpage&amp;diff=23514"/>
		<updated>2021-12-14T14:09:19Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Releases */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;div style=&amp;quot;text-align: right;&amp;quot;&amp;gt;[[Bestand:NL.png|link=ZIB_Hoofdpagina]] [[ZIB_Hoofdpagina|Nederlandse versie]]&amp;lt;/div&amp;gt;&lt;br /&gt;
== Health and Care information models == &lt;br /&gt;
Health and Care Information models (HCIM), or Clinical Buildingblocks (CBB&#039;s) or Zorginformatiebouwstenen (zib&#039;s) are used to capture functional, semantic (non technical) agreements for the standardization of information used in the care process. The purpose of the standardization is that this information from the care process is reused for other purposes such as quality registration, transfer or patient-related research. A HCIM is an information model in which a care-based concept is described in terms of the data elements from which that concept exists, the data types of those data elements, etc.&amp;lt;BR&amp;gt;&lt;br /&gt;
Health and Care Information models are information models of minimal clinical concepts, each containing multiple data with agreed content, structure and mutual relationship.&lt;br /&gt;
&lt;br /&gt;
== Release and maintenance process==&lt;br /&gt;
This wiki contains information about the three most recent publications of the HCIM&#039;s. Publications appear on average once a year and each contain a set of building blocks that are consistent. To implement HCIM&#039;s in accordance with a publication, all relevant HCIM&#039;s in the version as mentioned in the relevant publication summary should be used.&amp;lt;BR&amp;gt;&lt;br /&gt;
To meet the demand for flexibility for early adopters without undermining the desired and necessary stability, current developments are released in up to 4 pre-publications per year. These are consistent sets of HCIM&#039;s. However, there is no guarantee that these HCIM&#039;s will not be changed in the period until the next actual publication. Pre-publication users should realize this risk. Unlike publications, pre-publications will not remain available on this wiki but will be replaced by the following (pre-) publication.&amp;lt;BR&amp;gt;&amp;lt;BR&amp;gt;&lt;br /&gt;
The management process of the HCIM&#039;s is based on NEN7522.&amp;lt;BR&amp;gt; All details about this process, including the way in which change requests can be entered, are described in the document &amp;quot;Beheerafspraken zib&#039;s&amp;quot; [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/] (in Dutch).&lt;br /&gt;
&lt;br /&gt;
== Releases ==&lt;br /&gt;
At present the following releases are availabe:&lt;br /&gt;
*[[HCIM_Release_2015(EN)|release 2015]]&lt;br /&gt;
*[[HCIM_Release_2016(EN)|release 2016]]&lt;br /&gt;
*[[HCIM_Release_2017(EN)|release 2017]]&lt;br /&gt;
*[[HCIM_Release_2018(EN)|prerelease 2018-2]]&lt;br /&gt;
*[[HCIM_Release_2019(EN)|prerelease 2019-2]]&lt;br /&gt;
*[[HCIM_Release_2020(EN)|release 2020]]&lt;br /&gt;
*[[HCIM_Release_2021(EN)|prerelease 2021-2]]&lt;br /&gt;
&lt;br /&gt;
== Conditions ==&lt;br /&gt;
The health and care information models are made available under the following conditions:&lt;br /&gt;
&lt;br /&gt;
=== Disclaimer ===&lt;br /&gt;
The Health and Care Information Models (a.k.a Clinical Building Block) has been made in collaboration with several different parties in healthcare. These parties asked Nictiz to manage good maintenance and development of the information models. Hereafter, these parties and Nictiz are referred to as the collaborating parties. The collaborating parties paid utmost attention to the reliability and topicality of the data in these Health and Care Information Models. Omissions and inaccuracies may however occur. The collaborating parties are not liable for any damages resulting from omissions or inaccuracies in the information provided, nor are they liable for damages resulting from problems caused by or inherent to distributing information on the internet, such as malfunctions, interruptions, errors or delays in information or services provide by the parties to you or by you to the parties via a website or via e-mail, or any other digital means. The collaborating parties will also not accept liability for any damages resulting from the use of data, advice or ideas provided by or on behalf of the parties by means of the Health and Care Information Models. The parties will not accept any liability for the content of information in this Health and Care Information Model to which or from which a hyperlink is referred. In the event of contradictions in mentioned Health and Care Information Model documents and files, the most recent and highest version of the listed order in the revisions will indicate the priority of the documents in question. If information included in the digital version of a Health and Care Information Model is also distributed in writing, the written version will be leading in case of textual differences. This will apply if both have the same version number and date. A definitive version has priority over a draft version. A revised version has priority over previous versions.&lt;br /&gt;
&lt;br /&gt;
=== Terms of Use ===&lt;br /&gt;
The user may use the Health and Care Information Models without limitations. The copyright provisions in the paragraph concerned apply to copying, distributing and passing on the Health and Care Information Models.&lt;br /&gt;
&lt;br /&gt;
=== Copyrights ===&lt;br /&gt;
A Health and Care Information Model qualifies as a work within the meaning of Section 10 of the Copyright Act (Auteurswet). Copyrights protect the Health and Care Information Modesl and these rights are owned by the cooperating parties. &amp;lt;br&amp;gt;&lt;br /&gt;
The user may copy, distribute and pass on the information in this Health and Care Information Model under the conditions that apply for Creative Commons license Attribution-NonCommercial-ShareAlike 3.0 Netherlands (CC BY-NCSA-3.0).&amp;lt;br&amp;gt;&lt;br /&gt;
The content is available under Creative Commons Attribution-NonCommercial-ShareAlike 3.0 (see also http://creativecommons.org/licenses/by-nc-sa/3.0/nl/)[[Bestand:CreativeCommon.jpg|right|150px]]&amp;lt;br&amp;gt;&lt;br /&gt;
This does not apply to information from third parties that sometimes is used and / or referred to in a Health and Care Information Model, for example to an international medical terminology system. Any (copyright) rights that protect this information are not owned by the cooperating parties but by those third parties.&lt;br /&gt;
&lt;br /&gt;
== Wiki pagina&#039;s ==&lt;br /&gt;
&lt;br /&gt;
=== Use of the wiki pages ===&lt;br /&gt;
The wiki pages of the Health and Care Information Models are automatically generated from the original Enterprise Architect files from which the Health and Care Information Models PDFs are also created. This is done with the utmost care. However, if there are differences between the PDF and the wiki representation, the PDF representation including any patches is normative. Each wiki page lists which version of the PDF the wiki is based on, including the applicable patches.&lt;br /&gt;
&lt;br /&gt;
== Contact information ==&lt;br /&gt;
In addition to this wiki or the [https://www.nictiz.nl Nictiz website] you can also find relevant information on the national program &#039;Registratie aan de bron&#039; at the [https://www.registratieaandebron.nl Registratie aan de Bron website].&amp;lt;BR&amp;gt; &lt;br /&gt;
For all other information and questions, please contact the functional manager of the zib&#039;s via [mailto:info@nictiz.nl  info@nictiz.nl] or the general number of Nictiz (070 317 3450)&lt;br /&gt;
&lt;br /&gt;
== External links and background information ==&lt;br /&gt;
Relevant information on the health and care information models and their application can be found on the [https://www.nictiz.nl Nictiz website] and the [https://www.registratieaandebron.nl website of Registratie aan de Bron] (in Dutch) &amp;lt;BR&amp;gt;&lt;br /&gt;
In particular, the following document contains relevant background information.&lt;br /&gt;
* [[Media:HCIM_Architecture_Document_UK_v1.0.pdf |Architecture Document Volume 1]] [[File:PDF.png|link=]]&lt;br /&gt;
&lt;br /&gt;
Architecture Document Volumes 2-4 and the Service management agreements for Health and Care Information Models are at present only available in Dutch [[ZIB_Hoofdpagina#Externe links en achtergrondinformatie |(see Dutch page)]].&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=ZIB_Hoofdpagina&amp;diff=23513</id>
		<title>ZIB Hoofdpagina</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=ZIB_Hoofdpagina&amp;diff=23513"/>
		<updated>2021-12-14T14:08:54Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: /* Publicaties */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;div style=&amp;quot;text-align: right;&amp;quot;&amp;gt;[[Bestand:EN.png|link=HCIM_Mainpage]] [[HCIM_Mainpage|English version]]&amp;lt;/div&amp;gt;&lt;br /&gt;
== Zorginformatie bouwstenen == &lt;br /&gt;
Zorginformatiebouwstenen worden gebruikt om inhoudelijke (niet technische) afspraken vast te leggen ten behoeve van het standaardiseren van informatie, die gebruikt wordt in het zorgproces. Het doel van de standaardisatie is dat deze informatie uit het zorgproces wordt hergebruikt voor andere doeleinden zoals kwaliteitsregistraties, overdracht of patiëntgebonden onderzoek. Een zorginformatiebouwsteen is een informatiemodel, waarin een zorginhoudelijk concept wordt beschreven in termen van de gegevenselementen waaruit dat concept bestaat, de datatypes van die gegevenselementen etc.&amp;lt;BR&amp;gt;&lt;br /&gt;
Zorginformatiebouwstenen zijn informatiemodellen van minimale klinische concepten, die elk meerdere gegevens in zich herbergen met een afgesproken inhoud, structuur en onderlinge relatie.&lt;br /&gt;
&lt;br /&gt;
== Publicatie en beheersproces==&lt;br /&gt;
Deze wiki bevat informatie over de drie meest recente publicaties van de zorginformatiebouwstenen. Publicaties verschijnen gemiddeld één keer per jaar en bevatten telkens een set bouwsteenversies die in samenhang consistent zijn. Om zorginformatiebouwstenen conform een publicatie te implementeren dienen alle relevante zorginformatiebouwstenen in de versie zoals vermeld in het betreffende publicatieoverzicht gebruikt te worden.&amp;lt;BR&amp;gt;&lt;br /&gt;
Om tegemoet te komen aan de vraag om flexibiliteit ten behoeve van early adopters zonder de gewenste en noodzakelijke stabiliteit te ondermijnen, worden de lopende ontwikkelingen uitgebracht in maximaal 4 pre-publicaties per jaar.&amp;lt;BR&amp;gt;&lt;br /&gt;
Dit zijn op zich consistente sets zorginformatiebouwstenen. Er is echter geen garantie dat deze bouwstenen in de tijd tot volgende echte publicatie niet worden gewijzigd. Gebruikers van pre-publicaties dienen zich dit risico te realiseren.&amp;lt;BR&amp;gt;&lt;br /&gt;
In tegenstelling tot publicaties zullen pre-publicaties ook niet op deze wiki beschikbaar blijven maar vervangen worden door de volgende (pre-)publicatie.&amp;lt;BR&amp;gt;&amp;lt;BR&amp;gt;&lt;br /&gt;
Het beheerproces van de zib&#039;s is gebaseerd is op NEN7522.&amp;lt;BR&amp;gt; Alle details over dit proces, inclusief de manier waarop wijzigingsvoorstellen kunnen worden ingevoerd, staan beschreven in het document&lt;br /&gt;
&#039;Beheerafspraken Zorginformatiebouwstenen&#039; [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/]&lt;br /&gt;
&lt;br /&gt;
== Publicaties ==&lt;br /&gt;
Momenteel zijn de volgende publicaties beschikbaar&lt;br /&gt;
*[[ZIB_Publicatie_2015(NL)|publicatie 2015]]&lt;br /&gt;
*[[ZIB_Publicatie_2016(NL)|publicatie 2016]]&lt;br /&gt;
*[[ZIB_Publicatie_2017(NL)|publicatie 2017]]&lt;br /&gt;
*[[ZIB_Publicatie_2018(NL)|prepublicatie 2018-2]]&lt;br /&gt;
*[[ZIB_Publicatie_2019(NL)|prepublicatie 2019-2]]&lt;br /&gt;
*[[ZIB_Publicatie_2020(NL)|publicatie 2020]]&lt;br /&gt;
*[[ZIB_Publicatie_2021(NL)|prepublicatie 2021-2]]&lt;br /&gt;
&lt;br /&gt;
== Voorwaarden ==&lt;br /&gt;
De zorginformatie bouwstenen worden onder de volgende voorwaarden ter beschikking gesteld:&lt;br /&gt;
&lt;br /&gt;
=== Disclaimer ===&lt;br /&gt;
De Zorginformatiebouwstenen zijn in samenwerking gemaakt door diverse partijen en zij hebben deze in beheer gegeven bij Nictiz (al deze partijen samen hierna de samenwerkende partijen genoemd). De samenwerkende partijen hebben de grootst mogelijke zorg besteed aan de betrouwbaarheid en actualiteit van de gegevens in de Zorginformatiebouwstenen. Onjuistheden en onvolledigheden kunnen echter voorkomen. De samenwerkende partijen zijn niet aansprakelijk voor schade als gevolg van onjuistheden of onvolledigheden in de  aangeboden informatie, noch voor schade die het gevolg is van problemen veroorzaakt door, of inherent aan het verspreiden van informatie via het internet, zoals storingen of onderbrekingen van of fouten of vertraging in het verstrekken van informatie of diensten door de samenwerkende partijen of door u aan de samenwerkende partijen via een website of via e-mail, of anderszins. Tevens aanvaarden de samenwerkende partijen geen aansprakelijkheid voor eventuele schade die geleden wordt als gevolg van het gebruik van gegevens, adviezen of ideeën verstrekt door of namens de samenwerkende partijen via de Zorginformatiebouwstenen. De samenwerkende partijen aanvaarden geen verantwoordelijkheid voor de inhoud van informatie in de Zorginformatiebouwstenen waarnaar of waarvan met een hyperlink of anderszins wordt verwezen.In geval van tegenstrijdigheden in de genoemde Zorginformatiebouwsteen documenten en bestanden geeft de meest recente en hoogste versie van de vermelde volgorde in de revisies de prioriteit van de desbetreffende documenten weer.Indien informatie die in de elektronische versie van de Zorginformatiebouwstenen is opgenomen ook schriftelijk wordt verstrekt, zal in geval van tekstverschillen de schriftelijke versie bepalend zijn. Dit geldt indien de versieaanduiding en datering van beiden gelijk is. Een definitieve versie heeft prioriteit echter boven een conceptversie. Een gereviseerde versie heeft prioriteit boven een eerdere versie.&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Terms of Use ===&lt;br /&gt;
De gebruiker mag de Zorginformatiebouwstenen zonder beperking gebruiken. Voor het kopiëren, verspreiden en doorgeven van de Zorginformatiebouwstenen gelden de copyrightbepalingen uit de betreffende paragraaf. &amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Copyrights ===&lt;br /&gt;
Een Zorginformatiebouwsteen kwalificeert als een werk in de zin van artikel 10 Auteurswet. Er rusten auteursrechten (copyrights) op een Zorginformatiebouwsteen en deze rechten liggen bij de samenwerkende partijen.&amp;lt;br&amp;gt;&lt;br /&gt;
De gebruiker mag de informatie van de Zorginformatiebouwsteen kopiëren, verspreiden en doorgeven, onder de voorwaarden, die gelden voor Creative Commons licentie Naamsvermelding-NietCommercieel-GelijkDelen 3.0 Nederland (CC BY-NC-SA-3.0).&lt;br /&gt;
De inhoud is beschikbaar onder de Creative Commons Naamsvermelding-NietCommercieel-GelijkDelen 3.0 (zie ook http://creativecommons.org/licenses/by-nc-sa/3.0/nl/).[[Bestand:CreativeCommon.jpg|right|150px]]&amp;lt;br&amp;gt;&lt;br /&gt;
Dit geldt niet voor informatie van derden waar soms in een Zorginformatiebouwsteen gebruik van wordt gemaakt en/of naar wordt verwezen, bijvoorbeeld naar een internationaal medisch terminologie stelsel. De eventuele (auteurs) rechten die op deze informatie rusten, liggen niet bij de samenwerkende partijen maar bij die derden.&lt;br /&gt;
&lt;br /&gt;
== Wiki pagina&#039;s ==&lt;br /&gt;
&lt;br /&gt;
=== Gebruik van de wiki pagina&#039;s ===&lt;br /&gt;
De wiki pagina&#039;s van de zorginformatiebouwstenen worden automatisch gegenereeerd uit de oorspronkelijke Enterprise Architect bestanden waaruit ook de Zorginformatiebouwstenen PDF&#039;s worden gemaakt. Dit gebeurt met de grootste zorgvuldigheid. Mochten er desondanks verschillen zijn tussen de PDF en de wiki representatie dan is de PDF representatie incl. eventuele patches leidend. Op iedere wiki pagina staat vermeld op welke versie van de PDF de wiki is gebaseerd incl. de toegepaste patches.&lt;br /&gt;
&lt;br /&gt;
== Contactinformatie ==&lt;br /&gt;
Behalve de informatie op deze wiki of de informatie, die te vinden is op de [https://www.nictiz.nl Nictiz website]  kunt u ook op [https://www.registratieaandebron.nl Registratie aan de Bron website] de nodige informatie vinden over het landelijk programma &#039;Registratie aan de Bron&#039;. &lt;br /&gt;
Voor alle overige informatie en vragen kun u contact opnemen met de functioneel beheerder van de zib&#039;s via [mailto:beheerzib@nictiz.nl  beheerzib@nictiz.nl] of het algemene nummer van Nictiz (070- 317 3450)&lt;br /&gt;
&lt;br /&gt;
== Externe links en achtergrondinformatie==&lt;br /&gt;
Relevante documenten over de zorginformatiebouwstenen en de toepassing hiervan zijn te vinden op de [https://www.nictiz.nl Nictiz website] en de [https://www.registratieaandebron.nl  website van Registatie aan de Bron]&amp;lt;BR&amp;gt;&lt;br /&gt;
Met name de volgende documenten bevatten relevante achtergrondinformatie.&lt;br /&gt;
*[[Media:Architectuurdocument_Registratie_aan_de_bron_-_Volume_1_v1.1.pdf |Architectuurdocument Volume 1: De grondbeginselen van zorginformatiebouwstenen en hoe ze gebruikt kunnen worden]][[File:PDF.png|link=]]&lt;br /&gt;
*[[Media:Architectuurdocument_Registratie_aan_de_bron_-_Volume_2_v1.0.pdf |Architectuurdocument Volume 2: De praktische aspecten van de implementatie van zib&#039;s op het niveau van de applicaties en de gegevensuitwisseling]][[File:PDF.png|link=]]&lt;br /&gt;
*Architectuurdocument Volume 3: De praktische aspecten van de implementatie van zib&#039;s op het niveau van het zorgproces, use cases en gegevenssets (volgt binnenkort)&lt;br /&gt;
*[[Media:Architectuurdocument_Registratie_aan_de_bron_-_Volume_4_v1.pdf |Architectuurdocument Volume 4: De manier waarop zib&#039;s gebruikt kunnen worden voor de aanlevering aan registraties]][[File:PDF.png|link=]]&lt;br /&gt;
*[[Media:Beheerafspraken zorginformatiebouwstenen V1.0.pdf |Beheerafspraken Zorginformatiebouwstenen]][[File:PDF.png|link=]]&lt;br /&gt;
&lt;br /&gt;
==Factsheets Zorginformatiebouwstenen==&lt;br /&gt;
&amp;lt;span&amp;gt;Om meer inzicht te geven welke zorginformatiebouwsteen op welk moment te gebruiken zijn er factsheets ontwikkeld. Deze zijn te vinden op deze wiki op de volgende pagina: &#039;&#039;[[Factsheets Zorginformatiebouwstenen|Factsheets zibs]]&#039;&#039;&amp;lt;/span&amp;gt;.&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=22378</id>
		<title>HCIM Release 2021(EN)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=HCIM_Release_2021(EN)&amp;diff=22378"/>
		<updated>2021-12-14T13:39:47Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: Nieuwe pagina aangemaakt met &amp;#039;{{DISPLAYTITLE:HCIM Prerelease 2021-2(EN)}} &amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt; {{HCIMReleases(EN)|{{PAGENAMEE}}}} &amp;lt;!-- Tot hier de transclude...&amp;#039;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:HCIM Prerelease 2021-2(EN)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(EN)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Prerelease 2021-2 ==&lt;br /&gt;
This is a prerelease. More information about prereleases and releases you can find [[HCIM_Mainpage#Release and maintenance process | here]].&amp;lt;br&amp;gt;&lt;br /&gt;
The following summary shows which hcim&#039;s are part of this release, including the version numbers.&amp;lt;BR&amp;gt;&lt;br /&gt;
More information on Prerelease 2021-2 you can find in the [[Media:Prepublicatieversie 2021-2- Zorginformatiebouwstenen.pdf|ReleaseNotes 2021]] [[File:PDF.png|link=]] (in Dutch) and in the [[#New information models and deprecated information models in release 2020 | sections below]].&lt;br /&gt;
&lt;br /&gt;
== Health and care information models prerelease&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Administrative, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareTeam-v1.0.1(2021EN)|CareTeam-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Encounter-v4.0.2(2021EN)|Encounter-v4.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[HealthProfessional-v3.5.1(2021EN)|HealthProfessional-v3.5.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Payer-v3.2(2021EN)|Payer-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ContactPerson-v3.5(2021EN)|ContactPerson-v3.5]]&lt;br /&gt;
|[[HealthcareProvider-v3.4(2021EN)|HealthcareProvider-v3.4]]&lt;br /&gt;
|[[Patient-v4.0(2021EN)|Patient-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Clinical context, count&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021EN)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FeedingPatternInfant-v1.1.1(2021EN)|FeedingPatternInfant-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MultidisciplinaryTeamMeeting-v1.1(2021EN)|MultidisciplinaryTeamMeeting-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[SkinDisorder-v3.4(2021EN)|SkinDisorder-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergyIntolerance-v4.0(2021EN)|AllergyIntolerance-v4.0]]&lt;br /&gt;
|[[FeedingTubeSystem-v3.3.1(2021EN)|FeedingTubeSystem-v3.3.1]]&lt;br /&gt;
|[[NutritionAdvice-v3.2(2021EN)|NutritionAdvice-v3.2]]&lt;br /&gt;
|[[SOAPReport-v1.1(2021EN)|SOAPReport-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BladderFunction-v3.2(2021EN)|BladderFunction-v3.2]]&lt;br /&gt;
|[[FunctionalOrMentalStatus-v3.2.1(2021EN)|FunctionalOrMentalStatus-v3.2.1]]&lt;br /&gt;
|[[PainCharacteristics-v1.0(2021EN)|PainCharacteristics-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021EN)|Stoma-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BowelFunction-v3.1.2(2021EN)|BowelFunction-v3.1.2]]&lt;br /&gt;
|[[HearingFunction-v3.2.1(2021EN)|HearingFunction-v3.2.1]]&lt;br /&gt;
|[[Pregnancy-v4.1(2021EN)|Pregnancy-v4.1]]&lt;br /&gt;
|[[Vaccination-v4.1(2021EN)|Vaccination-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Burnwound-v3.5(2021EN)|Burnwound-v3.5]]&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|[[PressureUlcer-v3.4(2021EN)|PressureUlcer-v3.4]]&lt;br /&gt;
|[[VisualFunction-v3.3(2021EN)|VisualFunction-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DevelopmentChild-v1.2(2021EN)|DevelopmentChild-v1.2]]&lt;br /&gt;
|[[Infusion-v3.4(2021EN)|Infusion-v3.4]]&lt;br /&gt;
|[[Problem-v4.5(2021EN)|Problem-v4.5]]&lt;br /&gt;
|[[Wound-v3.4(2021EN)|Wound-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[EpisodeOfCare-v1.0(2021EN)|EpisodeOfCare-v1.0]]&lt;br /&gt;
|[[MedicalDevice-v3.4(2021EN)|MedicalDevice-v3.4]]&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Measurements, count&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BloodPressure-v3.2.1(2021EN)|BloodPressure-v3.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DAS-v1.1(2021EN)|DAS-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoryTestResult-v5.0(2021EN)|LaboratoryTestResult-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Respiration-v3.2(2021EN)|Respiration-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyHeight-v3.1.1(2021EN)|BodyHeight-v3.1.1]]&lt;br /&gt;
|[[FluidBalance-v1.0.1(2021EN)|FluidBalance-v1.0.1]]&lt;br /&gt;
|[[O2Saturation-v4.0(2021EN)|O2Saturation-v4.0]]&lt;br /&gt;
|[[TextResult-v4.4(2021EN)|TextResult-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyTemperature-v3.1.2(2021EN)|BodyTemperature-v3.1.2]]&lt;br /&gt;
|[[HeadCircumference-v1.3(2021EN)|HeadCircumference-v1.3]]&lt;br /&gt;
|[[PulseRate-v3.3(2021EN)|PulseRate-v3.3]]&lt;br /&gt;
|[[VisualAcuity-v2.0(2021EN)|VisualAcuity-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BodyWeight-v3.2(2021EN)|BodyWeight-v3.2]]&lt;br /&gt;
|[[HeartRate-v3.4.1(2021EN)|HeartRate-v3.4.1]]&lt;br /&gt;
|[[Refraction-v1.1(2021EN)|Refraction-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Medication, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdministrationAgreement-v1.1(2021EN)|AdministrationAgreement-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationAdministration2-v1.1.1(2021EN)|MedicationAdministration2-v1.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationContraIndication-v1.1(2021EN)|MedicationContraIndication-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicationUse2-v1.2(2021EN)|MedicationUse2-v1.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DispenseRequest-v1.1(2021EN)|DispenseRequest-v1.1]]&lt;br /&gt;
|[[MedicationAgreement-v1.3(2021EN)|MedicationAgreement-v1.3]]&lt;br /&gt;
|[[MedicationDispense-v2.1(2021EN)|MedicationDispense-v2.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Partial information models, count&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AddressInformation-v1.1(2021EN)|AddressInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ContactInformation-v1.2.1(2021EN)|ContactInformation-v1.2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NameInformation-v1.1(2021EN)|NameInformation-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Range-v1.0.1(2021EN)|Range-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomicalLocation-v1.0.1(2021EN)|AnatomicalLocation-v1.0.1]]&lt;br /&gt;
|[[InstructionsForUse-v1.3(2021EN)|InstructionsForUse-v1.3]]&lt;br /&gt;
|[[PharmaceuticalProduct-v2.1.3(2021EN)|PharmaceuticalProduct-v2.1.3]]&lt;br /&gt;
|[[TimeInterval-v1.1(2021EN)|TimeInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Patient context, count&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AdvanceDirective-v4.0(2021EN)|AdvanceDirective-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FamilySituation-v3.3(2021EN)|FamilySituation-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LegalSituation-v3.0(2021EN)|LegalSituation-v3.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ParticipationInSociety-v3.1(2021EN)|ParticipationInSociety-v3.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AlcoholUse-v3.3(2021EN)|AlcoholUse-v3.3]]&lt;br /&gt;
|[[FamilySituationChild-v1.3(2021EN)|FamilySituationChild-v1.3]]&lt;br /&gt;
|[[LifeStance-v3.2.1(2021EN)|LifeStance-v3.2.1]]&lt;br /&gt;
|[[TobaccoUse-v3.3(2021EN)|TobaccoUse-v3.3]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugUse-v3.4(2021EN)|DrugUse-v3.4]]&lt;br /&gt;
|[[HelpFromOthers-v3.01(2021EN)|HelpFromOthers-v3.01]]&lt;br /&gt;
|[[LivingSituation-v3.4(2021EN)|LivingSituation-v3.4]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Education-v3.2(2021EN)|Education-v3.2]]&lt;br /&gt;
|[[IllnessPerception-v3.1.1(2021EN)|IllnessPerception-v3.1.1]]&lt;br /&gt;
|[[MaritalStatus-v3.1(2021EN)|MaritalStatus-v3.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[FamilyHistory-v3.2(2021EN)|FamilyHistory-v3.2]]&lt;br /&gt;
|[[LanguageProficiency-v3.2(2021EN)|LanguageProficiency-v3.2]]&lt;br /&gt;
|[[Nationality-v3.0(2021EN)|Nationality-v3.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Scales en screening tools, count&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021EN)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021EN)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[PainScore-v4.0(2021EN)|PainScore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021EN)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelADLIndex-v3.1(2021EN)|BarthelADLIndex-v3.1]]&lt;br /&gt;
|[[FLACCpainScale-v1.1(2021EN)|FLACCpainScale-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021EN)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassification-v2.0(2021EN)|TNMTumorClassification-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPainBehavior-v1.1(2021EN)|ChecklistPainBehavior-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021EN)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021EN)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScale-v1.1(2021EN)|ComfortScale-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021EN)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021EN)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Selfcare, count&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToDressOneself-v3.1.1(2021EN)|AbilityToDressOneself-v3.1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToGroom-v1.0.2(2021EN)|AbilityToGroom-v1.0.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AbilityToPerformNursingActivities-v1.0.1(2021EN)|AbilityToPerformNursingActivities-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ToiletUseAbility-v3.1.1(2021EN)|ToiletUseAbility-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToDrink-v3.1.2(2021EN)|AbilityToDrink-v3.1.2]]&lt;br /&gt;
|[[AbilityToManageMedication-v1.0.1(2021EN)|AbilityToManageMedication-v1.0.1]]&lt;br /&gt;
|[[AbilityToWashOneself-v3.1.1(2021EN)|AbilityToWashOneself-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[AbilityToEat-v3.1.1(2021EN)|AbilityToEat-v3.1.1]]&lt;br /&gt;
|[[AbilityToPerformMouthcareActivities-v3.1(2021EN)|AbilityToPerformMouthcareActivities-v3.1]]&lt;br /&gt;
|[[Mobility-v3.3.1(2021EN)|Mobility-v3.3.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== group&amp;lt;!--rlGroup--&amp;gt;: Treatment, count&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[CareAgreement-v1.0(2021EN)|CareAgreement-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[NursingIntervention-v4.0(2021EN)|NursingIntervention-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Procedure-v5.3(2021EN)|Procedure-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TreatmentObjective-v3.2(2021EN)|TreatmentObjective-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FreedomRestrictingIntervention-v1.1(2021EN)|FreedomRestrictingIntervention-v1.1]]&lt;br /&gt;
|[[OutcomeOfCare-v3.3(2021EN)|OutcomeOfCare-v3.3]]&lt;br /&gt;
|[[TreatmentDirective2-v1.0(2021EN)|TreatmentDirective2-v1.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== New information models in prerelease 2021-2 ==&lt;br /&gt;
In prerelease 2021-2 a number of new information models are added to the national set of HCIM&#039;s.&amp;lt;br&amp;gt;&lt;br /&gt;
===New HCIM&#039;s===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|[[Reaction-v1.0(2021EN)|Reaction-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hypersensitivity-v1.0(2021EN)|Hypersensitivity-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Pre-release 2021-2 was published by adhering to a novel improved pre-publication procedure of the HCIM. For more information, click [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ here]. One of the features of this improved procedure method is that important changes to existing HCIMs and new HCIMs are first published in a pre-release and will no longer automatically end up in the next release. The new Hypersensitivity and Reaction HCIMs are examples of new HCIMs that are now being published in pre-release so that they can be used in a limited number of use cases. For that limited number of use cases, the new Hypersensitivity and Reaction HCIMs replace the existing Allergy Intolerance HCIM. In accordance with the improved procedure or pre-release, the decision whether these 2 new HCIMs will replace the existing Allergy Intolerance HCIM will be taken later in the preparations for a new release. As a consequence, the existing Allergy Intolerance HCIM is also still included in this pre-release, in addition to the 2 new HCIMs mentioned. Allergy Intolerance will remain valid for use cases for which the new Hypersensitivity and Reaction HCIMs will not be used.&lt;br /&gt;
&lt;br /&gt;
== Special information models ==&lt;br /&gt;
{{HCIM_PartialInformationModels_Include}}&lt;br /&gt;
{{HCIM_Templates_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
At the bottom of each HCIM wikipage you can find links to download the HCIM information in PDF of XLSX format.&amp;lt;BR&amp;gt;&lt;br /&gt;
It is also possible to download the whole set of HCIM&#039;s of this release in one file as [[Media:HCIM2020(PDF).zip |PDF]][[File:ZIP.png|link=]](50 MB), [[Media:HCIM2020(XLSX).zip|XLSX]][[File:ZIP.png|link=]] or [[Media:ZIBS2020(XMI).zip |XMI]][[File:ZIP.png|link=]]. The last file also contains valuelist in XML format.&lt;br /&gt;
&lt;br /&gt;
== Additional information ==&lt;br /&gt;
NEW!&lt;br /&gt;
* Starting from prepublication 2018-1, LOINC and SNOMED CT terms are displayed in Dutch wikipages in Dutch and in English wikipages in English, if an official translation is available.&lt;br /&gt;
:Attention! Publication 2020 contains many newly created SNOMED CT codes. These codes are not yet included in the current SNOMED CT release at the time of publication. As a result, these codes are incorrectly referred to as &#039;unknown code&#039;.&lt;br /&gt;
: This will be resolved after the new SNOMED CT release.&lt;br /&gt;
* A section has been added to each HCIM wikipage indicating which other HCIM&#039;s the building block refers to and in which other HCIM&#039;s the HCIM is used.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
	<entry>
		<id>https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=22377</id>
		<title>ZIB Publicatie 2021(NL)</title>
		<link rel="alternate" type="text/html" href="https://zibs.test-nictiz.nl/index.php?title=ZIB_Publicatie_2021(NL)&amp;diff=22377"/>
		<updated>2021-12-14T13:39:14Z</updated>

		<summary type="html">&lt;p&gt;Ali Zada: Nieuwe pagina aangemaakt met &amp;#039;{{DISPLAYTITLE:Zib Pre-publicatie 2021-2(NL)}} &amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt; {{HCIMReleases(NL)|{{PAGENAMEE}}}} &amp;lt;!-- Tot hier de transclu...&amp;#039;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;{{DISPLAYTITLE:Zib Pre-publicatie 2021-2(NL)}}&lt;br /&gt;
&amp;lt;!-- Hieronder wordt een transclude page aangeroepen --&amp;gt;&lt;br /&gt;
{{HCIMReleases(NL)|{{PAGENAMEE}}}}&lt;br /&gt;
&amp;lt;!-- Tot hier de transclude page --&amp;gt;&lt;br /&gt;
== Pre-publicatie 2021-2 ==&lt;br /&gt;
Dit is een pre-publicatie. Meer informatie over pre-publicaties en publicaties is [[ZIB_Hoofdpagina#Publicatie en beheersproces | hier]] te vinden.&amp;lt;br&amp;gt;&lt;br /&gt;
In onderstaand overzicht staat aangegeven welke zibs deel uitmaken van deze publicatie inclusief de versienummers.&amp;lt;BR&amp;gt;&lt;br /&gt;
Meer informatie over de pre-publicatie 2021-2 kunt u vinden in de [[Media:Prepublicatieversie 2021-2- Zorginformatiebouwstenen.pdf |ReleaseNotes 2021-2]] [[File:PDF.png|link=]] en de [[#Nieuwe bouwstenen in pre-publicatie 2021-2 | secties hieronder]].&lt;br /&gt;
&lt;br /&gt;
== Zorginformatiebouwstenen pre-publicatie&amp;lt;!--rlPreHeader--&amp;gt; 2021-2 ==&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Administratief, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Betaler-v3.2(2021NL)|Betaler-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Contactpersoon-v3.5(2021NL)|Contactpersoon-v3.5]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgaanbieder-v3.4(2021NL)|Zorgaanbieder-v3.4]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Zorgverlener-v3.5.1(2021NL)|Zorgverlener-v3.5.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Contact-v4.0.2(2021NL)|Contact-v4.0.2]]&lt;br /&gt;
|[[Patient-v4.0(2021NL)|Patient-v4.0]]&lt;br /&gt;
|[[ZorgTeam-v1.0.1(2021NL)|ZorgTeam-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Behandeling, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[BehandelAanwijzing2-v1.0(2021NL)|BehandelAanwijzing2-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[UitkomstVanZorg-v3.3(2021NL)|UitkomstVanZorg-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verrichting-v5.3(2021NL)|Verrichting-v5.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ZorgAfspraak-v1.0(2021NL)|ZorgAfspraak-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Behandeldoel-v3.2(2021NL)|Behandeldoel-v3.2]]&lt;br /&gt;
|[[VerpleegkundigeInterventie-v4.0(2021NL)|VerpleegkundigeInterventie-v4.0]]&lt;br /&gt;
|[[VrijheidsbeperkendeInterventie-v1.1(2021NL)|VrijheidsbeperkendeInterventie-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Klinische context, aantal&amp;lt;!--rlNumber--&amp;gt;: 27 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Alert-v4.1(2021NL)|Alert-v4.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FunctieZien-v3.3(2021NL)|FunctieZien-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Patientbespreking-v1.1(2021NL)|Patientbespreking-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Vaccinatie-v4.1(2021NL)|Vaccinatie-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AllergieIntolerantie-v4.0(2021NL)|AllergieIntolerantie-v4.0]]&lt;br /&gt;
|[[FunctioneleOfMentaleStatus-v3.2.1(2021NL)|FunctioneleOfMentaleStatus-v3.2.1]]&lt;br /&gt;
|[[Pijnkenmerken-v1.0(2021NL)|Pijnkenmerken-v1.0]]&lt;br /&gt;
|[[Voedingsadvies-v3.2(2021NL)|Voedingsadvies-v3.2]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Blaasfunctie-v3.2(2021NL)|Blaasfunctie-v3.2]]&lt;br /&gt;
|[[Huidaandoening-v3.4(2021NL)|Huidaandoening-v3.4]]&lt;br /&gt;
|[[Probleem-v4.5(2021NL)|Probleem-v4.5]]&lt;br /&gt;
|[[VoedingspatroonZuigeling-v1.1.1(2021NL)|VoedingspatroonZuigeling-v1.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Brandwond-v3.5(2021NL)|Brandwond-v3.5]]&lt;br /&gt;
|[[Infuus-v3.4(2021NL)|Infuus-v3.4]]&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|[[Wond-v3.4(2021NL)|Wond-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Darmfunctie-v3.1.2(2021NL)|Darmfunctie-v3.1.2]]&lt;br /&gt;
|[[MedischHulpmiddel-v3.4(2021NL)|MedischHulpmiddel-v3.4]]&lt;br /&gt;
|[[SOEPVerslag-v1.1(2021NL)|SOEPVerslag-v1.1]]&lt;br /&gt;
|[[ZorgEpisode-v1.0(2021NL)|ZorgEpisode-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DecubitusWond-v3.4(2021NL)|DecubitusWond-v3.4]]&lt;br /&gt;
|[[OntwikkelingKind-v1.2(2021NL)|OntwikkelingKind-v1.2]]&lt;br /&gt;
|[[SondeSysteem-v3.3.1(2021NL)|SondeSysteem-v3.3.1]]&lt;br /&gt;
|[[Zwangerschap-v4.1(2021NL)|Zwangerschap-v4.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[FunctieHoren-v3.2.1(2021NL)|FunctieHoren-v3.2.1]]&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|[[Stoma-v3.3(2021NL)|Stoma-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Medicatie, aantal&amp;lt;!--rlNumber--&amp;gt;: 7 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieafspraak-v1.3(2021NL)|Medicatieafspraak-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[MedicatieGebruik2-v1.2(2021NL)|MedicatieGebruik2-v1.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Medicatieverstrekking-v2.1(2021NL)|Medicatieverstrekking-v2.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Verstrekkingsverzoek-v1.1(2021NL)|Verstrekkingsverzoek-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[MedicatieContraIndicatie-v1.1(2021NL)|MedicatieContraIndicatie-v1.1]]&lt;br /&gt;
|[[MedicatieToediening2-v1.1.1(2021NL)|MedicatieToediening2-v1.1.1]]&lt;br /&gt;
|[[Toedieningsafspraak-v1.1(2021NL)|Toedieningsafspraak-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Metingen, aantal&amp;lt;!--rlNumber--&amp;gt;: 15 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Ademhaling-v3.2(2021NL)|Ademhaling-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[LaboratoriumUitslag-v5.0(2021NL)|LaboratoriumUitslag-v5.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[O2Saturatie-v4.0(2021NL)|O2Saturatie-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[TekstUitslag-v4.4(2021NL)|TekstUitslag-v4.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Bloeddruk-v3.2.1(2021NL)|Bloeddruk-v3.2.1]]&lt;br /&gt;
|[[Lichaamsgewicht-v3.2(2021NL)|Lichaamsgewicht-v3.2]]&lt;br /&gt;
|[[Polsfrequentie-v3.3(2021NL)|Polsfrequentie-v3.3]]&lt;br /&gt;
|[[Visus-v2.0(2021NL)|Visus-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DAS-v1.1(2021NL)|DAS-v1.1]]&lt;br /&gt;
|[[Lichaamslengte-v3.1.1(2021NL)|Lichaamslengte-v3.1.1]]&lt;br /&gt;
|[[Refractie-v1.1(2021NL)|Refractie-v1.1]]&lt;br /&gt;
|[[Vochtbalans-v1.0.1(2021NL)|Vochtbalans-v1.0.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Hartfrequentie-v3.4.1(2021NL)|Hartfrequentie-v3.4.1]]&lt;br /&gt;
|[[Lichaamstemperatuur-v3.1.2(2021NL)|Lichaamstemperatuur-v3.1.2]]&lt;br /&gt;
|[[Schedelomvang-v1.3(2021NL)|Schedelomvang-v1.3]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Patiënten context, aantal&amp;lt;!--rlNumber--&amp;gt;: 17 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[AlcoholGebruik-v3.3(2021NL)|AlcoholGebruik-v3.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[GezinssituatieKind-v1.3(2021NL)|GezinssituatieKind-v1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Opleiding-v3.2(2021NL)|Opleiding-v3.2]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Woonsituatie-v3.4(2021NL)|Woonsituatie-v3.4]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BurgerlijkeStaat-v3.1(2021NL)|BurgerlijkeStaat-v3.1]]&lt;br /&gt;
|[[HulpVanAnderen-v3.01(2021NL)|HulpVanAnderen-v3.01]]&lt;br /&gt;
|[[ParticipatieInMaatschappij-v3.1(2021NL)|ParticipatieInMaatschappij-v3.1]]&lt;br /&gt;
|[[Ziektebeleving-v3.1.1(2021NL)|Ziektebeleving-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[DrugsGebruik-v3.4(2021NL)|DrugsGebruik-v3.4]]&lt;br /&gt;
|[[JuridischeSituatie-v3.0(2021NL)|JuridischeSituatie-v3.0]]&lt;br /&gt;
|[[Taalvaardigheid-v3.2(2021NL)|Taalvaardigheid-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Familieanamnese-v3.2(2021NL)|Familieanamnese-v3.2]]&lt;br /&gt;
|[[Levensovertuiging-v3.2.1(2021NL)|Levensovertuiging-v3.2.1]]&lt;br /&gt;
|[[TabakGebruik-v3.3(2021NL)|TabakGebruik-v3.3]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[Gezinssituatie-v3.3(2021NL)|Gezinssituatie-v3.3]]&lt;br /&gt;
|[[Nationaliteit-v3.0(2021NL)|Nationaliteit-v3.0]]&lt;br /&gt;
|[[Wilsverklaring-v4.0(2021NL)|Wilsverklaring-v4.0]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Scorelijsten, aantal&amp;lt;!--rlNumber--&amp;gt;: 14 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[ApgarScore-v1.1(2021NL)|ApgarScore-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[DOSScore-v1.0(2021NL)|DOSScore-v1.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Pijnscore-v4.0(2021NL)|Pijnscore-v4.0]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[StrongKidsScore-v1.1(2021NL)|StrongKidsScore-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[BarthelIndex-v3.1(2021NL)|BarthelIndex-v3.1]]&lt;br /&gt;
|[[FLACCpijnScore-v1.1(2021NL)|FLACCpijnScore-v1.1]]&lt;br /&gt;
|[[SNAQ65+Score-v1.2.1(2021NL)|SNAQ65+Score-v1.2.1]]&lt;br /&gt;
|[[TNMTumorClassificatie-v2.0(2021NL)|TNMTumorClassificatie-v2.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[ChecklistPijngedrag-v1.1(2021NL)|ChecklistPijngedrag-v1.1]]&lt;br /&gt;
|[[GlasgowComaScale-v3.3(2021NL)|GlasgowComaScale-v3.3]]&lt;br /&gt;
|[[SNAQrcScore-v1.1(2021NL)|SNAQrcScore-v1.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[ComfortScore-v1.1(2021NL)|ComfortScore-v1.1]]&lt;br /&gt;
|[[MUSTScore-v3.1(2021NL)|MUSTScore-v3.1]]&lt;br /&gt;
|[[SNAQScore-v3.2(2021NL)|SNAQScore-v3.2]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Subbouwstenen, aantal&amp;lt;!--rlNumber--&amp;gt;: 8 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Adresgegevens-v1.1(2021NL)|Adresgegevens-v1.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Bereik-v1.0.1(2021NL)|Bereik-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[FarmaceutischProduct-v2.1.3(2021NL)|FarmaceutischProduct-v2.1.3]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Naamgegevens-v1.1(2021NL)|Naamgegevens-v1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[AnatomischeLocatie-v1.0.1(2021NL)|AnatomischeLocatie-v1.0.1]]&lt;br /&gt;
|[[Contactgegevens-v1.2.1(2021NL)|Contactgegevens-v1.2.1]]&lt;br /&gt;
|[[GebruiksInstructie-v1.3(2021NL)|GebruiksInstructie-v1.3]]&lt;br /&gt;
|[[TijdsInterval-v1.1(2021NL)|TijdsInterval-v1.1]]&lt;br /&gt;
|}&lt;br /&gt;
==== groep&amp;lt;!--rlGroup--&amp;gt;: Zelfzorg, aantal&amp;lt;!--rlNumber--&amp;gt;: 10 ====&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|-&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[Mobiliteit-v3.3.1(2021NL)|Mobiliteit-v3.3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotMondverzorging-v3.1(2021NL)|VermogenTotMondverzorging-v3.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotVerpleegtechnischeHandelingen-v1.0.1(2021NL)|VermogenTotVerpleegtechnischeHandelingen-v1.0.1]]&lt;br /&gt;
|width=&amp;quot;25%&amp;quot; |[[VermogenTotZichWassen-v3.1.1(2021NL)|VermogenTotZichWassen-v3.1.1]]&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotDrinken-v3.1.2(2021NL)|VermogenTotDrinken-v3.1.2]]&lt;br /&gt;
|[[VermogenTotToiletgang-v3.1.1(2021NL)|VermogenTotToiletgang-v3.1.1]]&lt;br /&gt;
|[[VermogenTotZelfstandigMedicatiegebruik-v1.0.1(2021NL)|VermogenTotZelfstandigMedicatiegebruik-v1.0.1]]&lt;br /&gt;
|&lt;br /&gt;
|-&lt;br /&gt;
|[[VermogenTotEten-v3.1.1(2021NL)|VermogenTotEten-v3.1.1]]&lt;br /&gt;
|[[VermogenTotUiterlijkeVerzorging-v1.0.2(2021NL)|VermogenTotUiterlijkeVerzorging-v1.0.2]]&lt;br /&gt;
|[[VermogenTotZichKleden-v3.1.1(2021NL)|VermogenTotZichKleden-v3.1.1]]&lt;br /&gt;
|&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
== Nieuwe bouwstenen in pre-publicatie 2021-2==&lt;br /&gt;
In pre-publicatie 2021-2 zijn een aantal nieuwe bouwstenen toegevoegd aan de landelijke set van zibs.&lt;br /&gt;
===Nieuwe zibs===&lt;br /&gt;
&lt;br /&gt;
{| width=&amp;quot;1000&amp;quot; style=&amp;quot;background-color:#F8F8FF&amp;quot;&lt;br /&gt;
|[[Overgevoeligheid-v1.0(2021NL)|Overgevoeligheid-v1.0]]&lt;br /&gt;
|-&lt;br /&gt;
|[[Reactie-v1.0(2021NL)|Reactie-v1.0]]&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Pre-publicatie  2021-2 is tot stand gekomen door de verbeterde opzet voor pre-publicatie van de zibs toe te passen. Zie voor meer informatie [https://www.nictiz.nl/standaardisatie/zib-centrum/beheerproces-zibs/verbetering-opzet-pre-publicatie-zibs/ hier]. Een van de kenmerken van deze verbeterde opzet is dat belangrijke wijzigingen op bestaande zibs en nieuwe zibs eerst in een pre-publicatie gepubliceerd worden en niet meer automatisch in de eerst volgende publicatie terecht komen. De nieuwe zibs Overgevoeligheid en Reactie zijn voorbeelden van nieuwe zibs die nu in pre-Publicatie worden gepubliceerd, zodat ze voor een beperkt aantal use cases kunnen worden toegepast. Voor die beperkt aantal use cases vervangen de nieuwe zibs Overgevoeligheid en Reactie de bestaande zib AllergieIntollerantie. Conform de verbeterde opzet van pre-Publicaties wordt het besluit of deze 2 nieuwe zibs de bestaande zib AllergieIntollerantie vervangen, later, in de voorbereidingen voor een nieuwe Publicatie genomen. Het gevolg hiervan is dat, naast de genoemde 2 nieuwe zibs, ook de bestaande zib AllergieIntollerantie nog in deze pre-Publicatie staat opgenomen: deze blijft immers geldig voor de use cases, die de nieuwe zibs Overgevoeligheid en Reactie (nog) niet toepassen.&lt;br /&gt;
&lt;br /&gt;
== Speciale bouwstenen ==&lt;br /&gt;
{{ZIB_Subbouwstenen_Include}}&lt;br /&gt;
{{ZIB_Blauwdrukken_Include}}&lt;br /&gt;
&lt;br /&gt;
== Downloads ==&lt;br /&gt;
Onderaan de iedere ZIB wikipagina staan links om de betreffende ZIB in PDF of XLSX formaat te downlowden.&amp;lt;BR&amp;gt;&lt;br /&gt;
Ook is het mogelijk de hele set ZIB&#039;s van deze publicatie in één keer te downloaden als [[Media:ZIBS2021-2(PDF).zip |PDF]][[File:ZIP.png|link=]](63 MB), [[Media:ZIBS2021-2(XLSX).zip|XLSX]][[File:ZIP.png|link=]] of [[Media:ZIBS2021-2(XMI).zip |XMI]][[File:ZIP.png|link=]] bestanden. De laatste bevat tevens de waardenlijsten in XML formaat.&lt;br /&gt;
&lt;br /&gt;
== Overige punten ==&lt;br /&gt;
NIEUW!&lt;br /&gt;
*Vanaf prepublicatie 2018#1 worden LOINC en SNOMED CT termen, indien een officiële vertaling beschikbaar is, in de Nedelandse pagina&#039;s in het Nederlands weergegeven en in de Engelse in het Engels.&lt;br /&gt;
:Let op! Publicatie 2020 bevat veel nieuw aangemaakte SNOMED CT codes. Deze codes zitten op moment van publicatie nog niet in de huidige SNOMED CT release. Daardoor worden deze codes foutief aangeduid als &#039;onbekende code&#039;.&lt;br /&gt;
:Na het verschijnen van de nieuwe SNOMED CT release wordt dit opgelost.&lt;br /&gt;
*Aan iedere zib wiki pagina is een sectie toegevoegd die aangeeft naar welke andere zibs de bouwsteen verwijst en in welke andere zibs de zib wordt gebruikt.&lt;br /&gt;
&amp;lt;!--[Hier kan per publicatie evt. nog iets extra&#039;s toegevoegd worden.]&lt;br /&gt;
--&amp;gt;&lt;/div&gt;</summary>
		<author><name>Ali Zada</name></author>
	</entry>
</feed>